0001213900-19-023387.txt : 20191114 0001213900-19-023387.hdr.sgml : 20191114 20191114122808 ACCESSION NUMBER: 0001213900-19-023387 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191114 DATE AS OF CHANGE: 20191114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Heyu Biological Technology Corp CENTRAL INDEX KEY: 0001086303 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 870627910 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26731 FILM NUMBER: 191218249 BUSINESS ADDRESS: STREET 1: 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY STREET 2: BUSINESS OPERATION CENTER JIMEI DISTRICT CITY: XIAMEN CITY, FUJIAN PROVINCE STATE: F4 ZIP: 361022 BUSINESS PHONE: 86 158 5924 0902 MAIL ADDRESS: STREET 1: 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY STREET 2: BUSINESS OPERATION CENTER JIMEI DISTRICT CITY: XIAMEN CITY, FUJIAN PROVINCE STATE: F4 ZIP: 361022 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC WEBWORKS INC DATE OF NAME CHANGE: 19990715 10-Q 1 f10q0919_heyubiological.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission file number 000-26731

HEYU BIOLOGICAL TECHNOLOGY CORPORATION
(Exact name of registrant as specified in its charter)
Nevada		87-0627910
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Room 1901, Baotuo Building,

617 Sishui Street,

Huli District, Xiamen City,

Fujian Province, China

361009

(Address of principal executive offices)

(Zip Code)

(86) 158 5924 0902

(Telephone number, including area code)

4^thFloor, No. 10 Building,

Xinglin Bay Business Operation Center,

Jimei District, Xiamen City,

Fujian Province, China

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 1,032,466,000 shares as of November 12, 2019.

TABLE OF CONTENTS

Index to Form 10-Q

		Page
Part I

FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Condensed Consolidated Balance Sheets (Unaudited)	1

	Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)	2

	Condensed Consolidated Statement of Cash Flows (Unaudited)	3

	Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited)	4

	Notes to Condensed Consolidated Financial Statements (Unaudited)	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	17

Item 4.	Controls and Procedures	17

Part II

OTHER INFORMATION

Item 1.	Legal Proceedings	18

Item 1A.	Risk Factors	18

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	19

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, Financial Statements and Notes to Financial Statements contain forward-looking statements that discuss, among other things, future expectations and projections regarding future developments, operations and financial conditions. Forward-looking statements may appear throughout this report and other documents we file with the Securities and Exchange Commission (SEC), including without limitation, the following sections: Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q.

Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “will be,” “will continue,” “may,” “could,” “will likely result,” and similar expressions. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause our actual results to differ materially from those reflected in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Consolidated Balance Sheets

(Unaudited)

	September 30,			December 31,
	2019			2018

ASSETS

Current Assets
Cash and cash equivalents	$	452,318		$	37,555
Other receivables		24,566			21,324
Advances to suppliers		81,431			-
Inventory		311,134			-
Total current assets		869,449			58,879

Non-current Assets
Operating lease right-of-use asset		209,587			-
Total non-current assets		209,587			-

Total Assets	$	1,079,036		$	58,879

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities
Accounts payable and accrued expenses	$	111,718		$	16,628
Advances from customers		420,406			-
Income tax and other taxes payable		22			23
Operating lease liability - current portion		66,473			-
Related party payables		957,409			279,464
Total current liabilities		1,556,028			296,115

Noncurrent liabilities
Operating lease liability		143,325			-
Total noncurrent liabilities		143,325			-

Total Liabilities	$	1,699,353		$	296,115

Stockholders’ Deficit

Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 and 1,141,472,861 shares issued and outstanding respectively as of September 30, 2019 and December 31, 2018, respectively)		1,032,466			1,141,473
Shares to be cancelled		-			(109,007	)
Additional paid-in capital		17,149,050			17,149,050
Accumulated other comprehensive income		16,945			2,567
Accumulated deficit		(18,778,535	)		(18,421,319	)
Stockholders’ equity - HYBT and Subsidiaries		(580,074	)		(237,236	)
Noncontrolling interests in subsidiaries		(40,243	)		-
Total stockholders’ deficit		(620,317	)		(237,236	)

Total Liabilities and Stockholders’ Deficit	$	1,079,036		$	58,879

The accompanying notes are an integral part of these consolidated financial statements.

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Consolidated Statements of Operations and Comprehensive Income

(Unaudited)

	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2019			2018			2019			2018

Revenue, net	$	7,387		$	-		$	57,317		$	-

Cost of Revenue	$	3,666		$	-		$	31,938		$	-

Gross Profit	$	3,721		$	-		$	25,379		$	-

Operating expenses
Selling expenses		5,992			-			7,377			-
Administrative expenses		202,505			125,957			412,207			147,797
Total operating expenses		208,497			125,957			419,584

Loss on operations		(204,776	)		(125,957	)		(394,205	)		(147,797	)

Other Income(Expenses)		(370	)		-			(1,708	)

Loss on operations before income taxes		(205,146	)		(125,957	)		(395,913	)		(147,797	)

Income tax expense		-			-						-

Net Loss	$	(205,146	)	$	(125,957	)	$	(395,913	)	$	(147,797	)
Loss attributable to noncontrolling interests		(20,455	)		-			(38,697	)		-
Net loss attributable to HYBT shareholders		(184,691	)		(125,957	)		(357,216	)		(147,797	)

Other Comprehensive Income
Foreign currency translation adjustment		12,506			-			15,924			-
Total Comprehensive Loss	$	(172,185	)	$	(125,957	)	$	(341,292	)	$	(147,797	)
Total comprehensive income attributable to noncontrolling interests		(1,320	)		-			(1,546	)		-
Total comprehensive loss attributable to HYBT shareholders		(173,505	)		(125,957	)		(342,838	)		(147,797	)

Net loss per share - basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average shares - basic and diluted		1,019,289,346			1,032,266,000			1,660,239,731			636,661,604

The accompanying notes are an integral part of these consolidated financial statements.

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Consolidated Statements of Cash Flows

(Unaudited)

	For the Nine Months Ended September 30,
	2019				2018

CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$	(395,913	)	$	(147,797	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in assets and liabilities
Other receivables		(3,242	)		-
Advances to suppliers		(81,431	)		-
Inventory		(311,134	)		-
Operating lease right-of-use asset		(209,587	)		-
Accounts payable and accrued liabilities		95,090			(9,677	)
Advances from customers		420,406			-
Income tax and other taxes payable		(1	)		-
Lease liability		209,798			-
Net cash used from operating activities		(276,014	)		(157,474	)

CASH FLOWS FROM INVESTING ACTIVITIES		-			-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party lending		677,945			157,474
Net cash used in financing activities		677,945			157,474

Effect of exchange rate changes on cash		12,832			-

NET INCREASE IN CASH AND CASH EQUIVALENTS		414,763			-

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		37,555			-

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	452,318		$	-

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income tax	$	-		$	-

Non-cash activities
Shares issued for repayment of debt				$	10,000
Related party forgiveness of debt				$	52,087

The accompanying notes are an integral part of these condensed consolidated financial statements

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Condensed Consolidated Statements of Stockholders’ Deficit

(Unaudited)

	Heyu Biological Shareholders’ Equity
	Common Stock											Accumulated
	Number of shares			Par value			Shares to be cancelled		Additional Paid in Capital			Other Comprehensive Income		Accumulated Deficit			Non - controlling Interest		Total
Balance at January 1, 2018		150,642,240			150,642			-		17,968,787			-		(18,173,542	)		-		(54,113	)
																				-
1 for 464 reverse split		(150,317,580	)		(150,318	)		-		150,318			-		-			-		-
1 for 100 split		32,141,340			32,141			-		(32,141	)		-		-			-		-
Common stock issued April 13, 2018		1,000,000,000			1,000,000					(990,000	)									10,000
Waiver of payable to ex-shareholder										52,087										52,087
Loss for the period		-			-			-		-			-		(147,797	)		-		(147,797	)

Balance at September 30, 2018		1,032,466,000		$	1,032,466		$	-	$	17,149,050		$	-	$	(18,321,339	)	$	-	$	(139,823	)

	Common Stock											Accumulated
	Number of shares			Par value			Shares to be cancelled			Additional Paid in Capital		Other Comprehensive Income		Accumulated Deficit			Non - controlling Interest			Total
Balance at January 1, 2019		1,141,472,861			1,141,473			(109,007	)		17,149,050		2,567		(18,421,319	)		-			(237,236	)

Shares cancelled March 20, 2019		(109,006,861	)		(109,007	)		109,007			-		-		-			-			-
Foreign currency translation adjustment		-			-			-			-		14,378		-			(1,546	)		12,832
Loss for the period		-			-			-			-		-		(357,216	)		(38,697	)		(395,913	)

Balance at September 30, 2019		1,032,466,000		$	1,032,466		$	-		$	17,149,050	$	16,945	$	(18,778,535	)	$	(40,243	)	$	(620,317	)

The accompanying notes are an integral part of these consolidated financial statements.

Heyu Biological Technology Corporation

(Formerly known as Pacific Webworks, Inc.)

Notes to Condensed Consolidated Financial Statements

(Unaudited)

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

Heyu Biological Technology Corporation (the “Company”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016 the Company proposed a Plan of Liquidation and on November 28, 2016, the Court entered an order confirming the Plan of Liquidation and establishing a Liquidating Trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the Liquidating Trust.

On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company (“Common Stock”) from Mr. Masters for an aggregate purchase price of $335,000 (the “Share Purchase”). As a result of the Share Purchase Agreement, the Company accepted the resignation of Dan Masters, as the Company’s President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On April 18, 2018, to fill the vacancies created by Mr. Masters’s resignations, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board. Mr. Tan was appointed as Executive Director of the Company. Ms. Wendy Wei Li was appointed as Chief Financial Officer.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation, with a new ticker symbol, HYBT.

During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018 and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. Further, on November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC”) on November 16, 2017.

On January 17, 2019, JSEL entered into a Share Transfer Agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC, and who owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in the business of selling medical equipment. It was the parties’ intention that JSEL would fund the operations of Kangzi in proportion to its equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation of its own.

In March 2019, the Company entered into a Raspberry Purchase Agreement and a Raspberry Juice Processing Agreement with Luoyang Ditiantai Agricultural Development Co., Ltd. (“Ditiantai”). Pursuant to these two agreements, the Company purchased six tons of raspberry from Ditiantai, which were processed by Ditiantai into raspberry juice and delivered to the Company. The Company then sold the raspberry juice to a corporate buyer and five individual buyers. The Company, however, does not plan to engage in the business of selling raspberry juice in the long term.

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Specifically, we believe that exposure to an appropriate amount of submillimeter waves could accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancering process through which selenium is converted into nickel inside cells.

The team consists of researchers whom have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, as the chairman and chief scientist of Shanghai Guangcon New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu was rewarded the “Harmony-Person of the Year in China” at the “2011 Harmony China Annual Summit” in Beijing and recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of Boau Forum on Asian SME Development awarded Mr. Xu “2013 China Economic Outstanding Contribution Award.”

Pursuant to the terms of the Share Transfer Agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for the Chamber in September.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2019 and 2018 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company as of September 30, 2019, the results of its operations for the three and nine months ended September 30, 2019 and 2018, and its cash flows for the nine months ended September 30, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2018 has been derived from the Company’s audited financial statements included in the Form 10-K for the year ended December 31, 2018.

The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company’s Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2018.

As of September 30, 2019, the details of the consolidating subsidiaries are as follows:

Name of Company	Place of incorporation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	The PRC		100	%

Kangzi	The PRC		60	%

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities.

Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong.

Inventories

Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Leases

The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements.

Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.

ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2019		25,409
Fiscal 2020		77,074
Fiscal 2021		79,615
Fiscal 2022		54,206
Total Lease payments		236,304
Less Imputed interest		21,005
Present value of lease liabilities	$	215,298

Foreign Currency

For fiscal year 2019, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarter ended September 30, 2019 and 2018.

	As of
	September 30, 2019		December 31, 2018
RMB: US$ exchange rate		7.1360		6.8764

	Nine months ended September 30,
	2019		2018
RMB: US$ exchange rate		6.8618		6.6146

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

General and administrative costs

General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes

The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain.

The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions.

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

The Company had 2,000,000,000 shares of authorized common stock, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2019, and 1,141,472,861 shares issued and outstanding as of December 31, 2018.

Earnings (loss) per share

Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive.

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

As of September 30, 2019 and December 31, 2018, there were no potentially dilutive shares.

	For the Quarter Ended September 30,
	2019			2018
Statement of Operations Summary Information:
Net loss	$	(395,913	)	$	(147,797	)
Weighted-average common shares outstanding - basic and diluted		1,660,239,731			636,661,604
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

NOTE 2 – GOING CONCERN

During the quarter ended September 30, 2019, the Company had been unable to generate cash flows sufficient to support its operations despite of Kangzi’s business operation and had been dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $18,778,535 and working capital deficit of $686,579 as of September 30, 2019. These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there would be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals.

NOTE 3 – CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

	As of September 30, 2019		As of December 31, 2018

Bank Deposits-China & HK		452,318		37,555
	$	452,318	$	37,555

NOTE 4 – OTHER RECEIVABLE

Other receivable consists of the following:

	As of September 30, 2019		As of December 31, 2018

Fujian Shanzhiling Biological Technology Co., Ltd.		-		21,324
Others		24,566		-
	$	24,566	$	21,324

On October 8, 2018, the Company entered into a non-binding letter of intent with Fujian Shanzhiling Biological Technology Co., Ltd. (the “Acquirer”), a Chinese biotechnology product manufacturing corporation, whereby the Acquirer agreed to acquire 51% of the outstanding capital of the Company subject to certain adjustment provisions (the “Shanzhiling Acquisition”). As of the date of this report, the Company has terminated the agreements related to Shanzhiling Acquisition; therefore, the related balance in the amount of $24,499 has been written off during the quarter ended September 30, 2019.

NOTE 5 – ADVANCES TO SUPPLIERS

Advances to suppliers consists of the following:

	As of September 30, 2019		As of December 31, 2018

Prepayment for purchase of raw materials		81,431		-
	$	81,431	$	0

NOTE 6 – INVENTORY

Inventory consists of the following:

	As of September 30, 2019		As of December 31, 2018

Raw materials		301,725		-
Finished goods		9,409		-
	$	311,134	$	-

No impairment was provided for the inventories as of September 30, 2019.

NOTE 7 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

As of September 1, 2019, company entered in lease agreement for the office space, the right-of-use asset is recognized as following:

	As of September 30, 2019		As of December 31, 2018

Operating lease right-of-use asset		209,587		-
	$	209,587	$	-

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2019			As of December 31, 2018

Operating lease liability - current portion		(66,473	)		-
Operating lease liability		(143,325	)		-
	$	(209,798	)	$	-

	September 1, 2019
Weighted Average Remaining Lease Term (Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2019		25,409
Fiscal 2020		77,074
Fiscal 2021		79,615
Fiscal 2022		54,206
Total Lease payments		236,304
Less Imputed interest		21,005
Present value of lease liabilities	$	215,298

NOTE 8 – ADVANCES FROM CUSTOMERS

	As of September 30, 2019		As of December 31, 2018

Advances from customers⁽¹⁾		420,406		-
	$	420,406	$	-

⁽¹⁾

On October 15 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

NOTE 9 – ACCRUED EXPENSES AND OTHER PAYABLES

Accrued expenses and other payables consist of the following:

	As of September 30, 2019		As of December 31, 2018

Accrued payroll		35,633		7,589
Other Payables		76,085		9,039
	$	111,718	$	16,628

Accrued payroll includes all company employee payroll liabilities as of September 30, 2019, and other payables contains employee reimbursements.

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2019			As of December 31, 2018

Operating lease liability - current portion		(66,473	)		-
Operating lease liability		(143,325	)		-
	$	(209,798	)	$	-

NOTE 10 – RELATED PARTY TRANSACTIONS

As of September 30, 2019, and December 31, 2018, the Company owed related parties $957,409 and $279,464, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by a related party. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls.

A director of the Company provides the property for the use by the Company without charge.

NOTE 11 – EQUITY

The Company recorded the following equity transactions during the nine months ended September 30, 2019:

On March 15, 2019, the Company, with the approval of the Board, entered into a Share Cancellation Agreement (the “Share Cancellation Agreement”) with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of the Company. Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of Common Stock previously issued to Mr. Ang.

The Company recorded the following equity transactions during the year ended December 31, 2018:

On March 12, 2018, the Board of Directors, with the consent of the majority shareholder, voted for a 1-for-464 reverse stock split. On April 11, 2018 the reverse split became effective.

On April 13, 2018, 1,000,000,000 shares were issued to a prior related party as a repayment of debt.

On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of Common Stock from Mr. Masters for an aggregate purchase price of $335,000. As a result of the Share Purchase Agreement, the Company accepted the resignation of Mr. Masters, as the Company’s President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On July 30, 2018, the Company amended its Articles of Incorporation with the State of Nevada in order to increase its authorized shares of Common Stock from 150,000,000 to 2,000,000,000.

On September 11, 2018, the Nevada Secretary of State approved the Company’s certificate of amendment to amend its Articles of Incorporation to effectuate a 100-for-1 forward stock split. The total issued and outstanding shares of Common Stock has been increased from 10,324,660 to 1,032,466,000 shares, with the par value unchanged at $0.001.

In October 2018, the controlling stockholder of the Company, Mr. Ban Siong Ang, entered into a series of share transfer agreements (the “Share Transfer Agreements”) with certain buyers (the “Buyers”). Pursuant to the Share Transfer Agreements, an aggregate of 109,006,861 shares of Common Stock were issued to the Buyers, but the cancellation of the 109,006,861 shares of Common Stock held by Mr. Ang was still in process as of December 31, 2018. The cancellation of those shares held by Mr. Ang was subsequently completed on March 20, 2019, pursuant to a Share Cancellation Agreement dated March 15, 2019, by and between the Company and Mr. Ang.

Unless otherwise indicated, all common share amounts and per share amounts in the financial statements and disclosures have been presented giving effect to the 1-for-464 reverse split that became effective on April 11, 2018, and the 100-for-1 forward stock split that became effective on September 11, 2018.

NOTE 12 – INCOME TAXES

The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States.

Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong.

The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Statements made in this Quarterly Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and our business, including, without limitation, (i) our ability to raise capital, and (ii) statements preceded by, followed by or that include the words “may,” “would,” “could,” “should,” “expects,” “projects,” “anticipates,” “believes,” “estimates,” “plans,” “intends,” “targets” or similar expressions.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following: general economic or industry conditions, nationally and/or in the communities in which we may conduct business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, our ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting our current or potential business and related matters.

Accordingly, results actually achieved may differ materially from expected results in these statements. Forward-looking statements speak only as of the date they are made. We do not undertake, and specifically disclaim, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

Overview

Heyu Biological Technology Corporation (the “Company” or “we”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016, the Company proposed a Plan of Liquidation and on November 28, 2016, the Court entered an order confirming the Plan of Liquidation and establishing a Liquidating Trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the Liquidating Trust.

On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of Common Stock from Mr. Masters for an aggregate purchase price of $335,000. As a result of the Share Purchase Agreement, the Company accepted the resignation of Mr. Masters, as the Company’s President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On April 18, 2018, to fill the vacancies created by Mr. Masters’s resignations, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board of the Company. Mr. Tan was appointed as Executive Director of the Company. Ms. Wendy Li was appointed as Chief Financial Officer.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation, with a new ticker symbol, HYBT.

On January 17, 2019, JSEL, entered into the Share Transfer Agreement with Mr. Xu, whereby JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in the business of selling medical equipment. It was the parties’ intention that JSEL would fund the operations of Kangzi in proportion to its equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation of its own.

In March 2019, the Company entered into a Raspberry Purchase Agreement and a Raspberry Juice Processing Agreement with Ditiantai. Pursuant to these two agreements, the Company purchased six tons of raspberry from Ditiantai, which were processed by Ditiantai into raspberry juice and delivered to the Company. The Company then sold the raspberry juice to a corporate buyer and five individual buyers. The Company, however, does not plan to engage in the business of selling raspberry juice in the long term.

Pursuant to the terms of the Share Transfer Agreement entered into by JSEL and Kangzi on January 17, 2109, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for the Chamber in September. Subsequently, on October 15 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. During the clinical trial, JSEL shall provide training sessions regarding the proper operation of the Chamber to Saikun’s employees. Both Saikun and JSEL are obligated to find third-party hospitals whom will agree to act as partners to co-host the clinical trial and patients whom will be voluntarily willing to undergo treatment provided by the Chamber. While Saikun is responsible for various expenses related to the clinical trial, JSEL is responsible for communicating with patients receiving treatment and other patient-related administrative matters. When JSEL determines that Saikun is capable of properly operating the Chamber and managing activities related to the Chamber, Saikun may request JSEL to move the Chamber to a location designated by Saikun and reinstall it. Furthermore, upon the successful completion of the clinical trial, JSEL shall provide Saikun governmental permits necessary for the operation of the Chamber, and Saikun shall operate the Chamber and provide related services to patients under the supervision of JSEL. In addition, JSEL shall transfer the right of using the Chamber and any beneficiary right affiliated to using the Chamber to Saikun upon receiving the full amount of payment from Saikun. JSEL, nevertheless, owns all the intellectual property rights affiliated with the Chamber. If the two parties decide to terminate the Clinical Cooperation Agreement prior to the expiration of the term, Saikun’s right of using the Chamber during the term is still effective as long as its use of the Chamber does not infringe any of JSEL’s intellectual property rights affiliated with the Chamber. The two parties agreed that the term of the Clinical Cooperation Agreement would not end until Kangzi successfully obtains permits issued by relevant government entities supervising development and sale of medical equipment.

To prepare for the mass production of Chambers, Kangzi is conducting clinical experiments to make further improvements on Chamber and adjusting features of the mass-production mold for Chamber. Kangzi is also in the process of obtaining official governmental permits from relevant government authorities to produce and sell Chambers on a national scale. As its long-term business strategy, Kangzi focuses on researching, developing, and manufacturing high-technology medical equipment while targeting both individual and institutional customers. It plans to massively manufacture Chambers in small and medium sizes, establish operation centers to sell Chambers in various cities across China, and initiate advertising and marketing campaigns on different media platforms. Kangzi will also monetize on services provided to customers who use Chambers and other medical products.

In addition to business activities related to Chamber, the Company will commit to the research, development, manufacturing, and sale of healthcare equipment and various health products containing natural plateau plants, including cosmetics, nutritional supplements, and drugs. In the near future, the Company aims to standardize and internationalize the production and sale of healthcare equipment and health products, while increasing its brand awareness in the healthcare and consumer-product markets.

Liquidity and Capital Resources

As of September 30, 2019, we had assets of $1,079,036, which consisted current assets of $452,318 in cash, $24,566 in other receivables, $81,431 as advances to suppliers, and $311,134 as inventory, and noncurrent asset of $209,587 operating lease right-of-use asset.We had liabilities of $1,699,353, which consisted current liabilities of $111,718 in accounts payable and accrued expenses, $420,406 in advances from customers, $22 in taxes payable, $957,409 in related party payables and $66,473 in short term operating lease liabilities. We also had recognized long term operating lease liabilities of $143,325 as noncurrent liabilities. We had an accumulated deficit of $18,778,535.

As of December 31, 2018, we had assets of $58,879, liabilities of $296,115 and an accumulated deficit totaled $18,421,319. The increase in the assets was mainly due to cash balance increased by customer prepayments, increase of inventory in raw materials, and recognition of the operating lease right-of-use asset. The increase in the liabilities was mainly due to advanced payments received from customers, relevant operating lease liabilities, and related party payables. Additionally, as the Company started its operation in mid-March 2019, related parties paid expenses totaling $957,409 to vendors for accounting, auditing, consulting, SEC filing services, and all other operating expenses as of September 30, 2019.

Results of Operations

From the period of the Liquidation on December 28, 2016 to September 6, 2019, we had been a shell company without any significant assets or operations. Since September 7, 2019, we are no longer a shell company due to the business operation of Kangzi and the first amount of preordering payment received from Saikun. For a detailed description, please see “Overview” above.

Comparison of the Three Months Ended September 30, 2019 and 2018

We started operations in mid-March 2019, and had no revenues or operations for the same period in 2018. Our revenues during the three months ended September 30, 2019, were $7,387, and the cost of revenue was $3,666, as compared to nil and nil for the same period in 2018, respectively. The increase in revenues and cost of revenue was due to sale of raspberry juice during the period. We had incurred selling expenses of $5,992 and administrative expenses of $202,505 during the three months ended September 30, 2019, as compared to selling expenses of nil and administrative expenses of $125,957 for the same period in 2018, respectively. The increase in the expenditure was mainly due to office lease expenses, employee wages, and other third part agency fees. . We might incur operating expenses without sufficient revenues, as we have just identified and determined to focus on the research, development, and manufacturing of healthcare equipment and health products. We will depend upon our officers and directors to make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions. However, by the end of September we have received customer prepayments for our new medical product and services pursuant to the Clinical Cooperation Agreement. When we start fulfilling our obligations under the Clinical Cooperation Agreement, we expect to see significant increase in revenue.

Comparison of the Nine Months Ended September 30, 2019 and 2018

We started operations in mid-March 2019, and had no revenues or operations for the same period in 2018. Our revenues during the nine months ended September 30, 2019, were $57,317, and the cost of revenue was $31,938, as compared to nil and nil for the same period in 2018, respectively. The increase in revenues and cost of revenue was due to sale of raspberry juice during the period. We had incurred selling expenses of $7,377 and administrative expenses of $412,207 during the nine months ended September 30, 2019, as compared to selling expenses of nil and administrative expenses of $147,797 for the same period in 2018, respectively. The increase in the expenditure was mainly due to office lease expenses, employee wages and salary expenses, auditing, and other day-to-day operation related expenses. We might incur operating expenses without sufficient revenues, as we have just identified and determined to focus on the research, development, and manufacturing of healthcare equipment and health products. We will depend upon our officers and directors to make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions. However, by the end of September we have received customer prepayments for our new medical product and services pursuant to the Clinical Cooperation Agreement. When we start fulfilling our obligations under the Clinical Cooperation Agreement, we expect to see significant increase in revenue.

Going Concern

The accompanying financial statements are presented on a going concern basis. The Company’s financial condition raises doubt about the Company’s ability to continue as a going concern. As of September 30, 2019, the Company had an accumulated deficit of $18,778,535, and a net loss of $205,146 and $395,913 for the three and nine months ended September 30, 2019. As the development of the Chamber enters its final stage and our subsidiary, JSEL, has started accepting pre-orders for the Chamber in September, we believe that as the number of orders for the Chamber increases in the future the Company will generate more revenues enabling it to cover its operating expenses.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material to investors.

ITEM 3 QUANTITATIVE AND QUALITATIVE ABOUT MATERIAL RISKS

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were not effective as a result of a material weakness primarily related to a lack of a sufficient number of personnel with appropriate training and experience in accounting principles generally accepted in the United States of America, or GAAP. To remediate the material weakness, our Chief Financial Officer, as a member of CPA Australia, hence a Certified Public Accountant in Australia, has attended professional trainings regarding applying GAAP on a regular basis. In the near future, we also intend to hire more personnel with sufficient training and experience in GAAP.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarterly period ended September 30, 2019, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

ITEM 1A. RISK FACTORS

Smaller reporting companies are not required to provide the information required by this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

There were no unregistered sales of equity securities during the period covered by this report on Form 10-Q.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. – EXHIBITS

Exhibit		Exhibit Description
3.1⁽¹⁾		Articles of Incorporation
3.2 ⁽²⁾		Certificate of Amendment
3.3 ⁽³⁾		Certificate of Amendment
3.4⁽⁴⁾		Certificate of Amendment
3.5⁽⁵⁾		By-Laws
3.6⁽⁶⁾		First Amendment to the By-Laws
10.1*		Clinical Cooperation Agreement entered into and by Jiashierle (Xiamen) Healthcare Technology Co., Ltd. and Shenzhen Saikun Biotechnology Co., Ltd., dated October 15, 2019*
31.1*		Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

⁽¹⁾	Filed as an exhibit to the Company’s Registration Statement on Form 10-12G, as filed with the SEC on July 16, 1999, and incorporated herein by this reference.
⁽²⁾	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 6, 2018, and incorporated herein by reference.
⁽³⁾	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on August 3, 2018, and incorporated herein by reference.
⁽⁴⁾	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on September 14, 2018, and incorporated herein by reference.
⁽⁵⁾	Filed as an exhibit to the Company’s Registration Statement on Form 10-12G, as filed with the SEC on July 16, 1999, and incorporated herein by this reference.
⁽⁶⁾	Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q, as filed with the SEC on November 13, 2018, and incorporated herein by this reference.

Filed herewith.

In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 herewith are deemed to accompany this Form 10-Q and will not be deemed filed for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Heyu Biological Technology Corporation

	By:	/s/ Ban Siong Ang
	Name:	Ban Siong Ang
Dated: November 14, 2019	Title:	Chief Executive Officer

	By:	/s/ Wendy Wei Li
	Name:	Wendy Wei Li
Dated: November 14, 2019	Title:	Chief Financial Officer

EX-10.1 2 f10q0919ex10-1_heyubiologi.htm CLINICAL COOPERATION AGREEMENT ENTERED INTO AND BY JIASHIERLE (XIAMEN) HEALTHCARE TECHNOLOGY CO., LTD. AND SHENZHEN SAIKUN BIOTECHNOLOGY CO., LTD., DATED OCTOBER 15, 2019

Exhibit 10.1

Cooperation Agreement

Party A: Shenzhen Saikun Biotechnology Co., Ltd.

Legal Representative: Chunjie Zhang

Party B: Jiashierle (Xiamen) Health Science & Technology Co., Ltd.

Legal Representative: TAN HUNG SENG

In the light of:

1. Both Party A and Party B are enterprises legally established and existing under the laws of PRC. Shanghai Kangzi Pharmaceutical Science & Technology Co., Ltd. is a subsidiary of Party B with its shares controlled by Party B (as of the date of this Agreement, Party B holds 60% of shares). The quantized spatial power chamber (hereinafter collectively “remedial chambers”) developed by Shanghai Kangzi Pharmaceutical Science & Technology Co., Ltd. is in the term of clinical trial.

2. Both Party A and Party B have abundant knowledge about the application and marketing prospects of remedial chambers and have reached agreements on the clinical trial and marketing promotion of remedial chambers.

-1-

Therefore, for facilitating the progress of clinical cooperation and advertising the remedial chambers to market as soon as possible, Party A and Party B have reached the following agreements through negotiation:

1. Forms and Contents of Cooperation

The Party A shall provide support funds of five million and fifty thousand RMB (¥5,500,000) for the cooperation, while Party B shall be responsible for selecting and purchasing raw materials of remedial chambers as well as providing one assembled equipment for clinical trial. After fulfilling the payment of whole funds, Party A shall have the rights of use and the derivative interests.

2. Payment of Funds

2.1 Time of Payment

2.1.1 Both Party A and Party B have confirmed that Party A has paid the first sum of funds of one million and fifty thousand RMB (¥1,500,000) to the account designated by Party B on September 7th 2019 and have paid one million and fifty thousand RMB (¥1,500,000) to the account designated by Party B on September 27th 2019. As of the date of signing this Agreement, Party A has paid a total of three million RMB (¥3,000,000) for cooperation support funds.

-2-

2.1.2 As Party A agreed, it shall pay two million and fifty thousand RMB (¥2,500,000) to Party B before October 15th 2019.

2.2 Payment Method

2.2.1 Party shall pay the support funds aforesaid to the account designated by Party B as followed:

Name of Account: Jiashierle (Xiamen) Health Science & Technology Co., Ltd.

Account Number: 403210 010400 XXXXX

Opening Bank: Agricultural Bank of China Xiamen Jimei Subbranch

2.2.2 In the event Party A requests Party B to provide bills, Party A shall provide official proof on relationships between payer and Party A (or its legal representative), in order for Party B to provide bills.

-3-

3. Rights and Obligations

3.1 Installation and Transportation. Party B shall finish purchasing required raw materials for one remedial chamber and hereby installing and transporting to the place designated by Party B as known and agreed by Party A, within 30 days after receiving total support funds of five million and fifty thousand RMB (¥5,500,000) that shall be paid by Party A, and to complete equipment testing and other work.

3.2 Clinical Trial

3.2.1 As agreed by both Party, a clinical trial no less than one month shall be carried out, after the installation and adjustment of the remedial chamber.

3.2.2 During clinical trial, Party B shall be responsible for training operators required for clinical trial to operate remedial chamber equipment skillfully.

-4-

3.2.3 Party A shall be responsible for coordinating with official competent authority to ensure that such remedial chamber can normally carry out clinical trials at the site provided by Party A and shall be responsible for providing operators and site administrators required for clinical trials and arranging corresponding medical personnel. During the trial period, all expenses of relevant staff such as salary, training expenses, labor and social security expenses shall be borne by Party A.

3.2.4 Both Party A and Party B have obligation to provide clinical cases required for clinical trials in accordance with standards, to invite presidents of regional major hospitals to observe and experience in the test site during the trial period. Party A shall assist clinical hospitals with relevant clinical work and shall bear the costs and enjoy the benefits. Party B shall actively cooperate in introduction for patient and follow-up maintenance during the clinical trial period.

-5-

3.3 Both parties agree that when Party A has been able to operate and manage the remedial chamber equipment independently, Party A may request the equipment to be modified to the place designated by Party A, provided that the place shall meet clinical conditions.

3.4 The warranty period of the remedial chamber is one year, counting from the date when the remedial chamber is transported to the designated place. During the warranty period, in the event Party A requests to upgrade and transform the equipment, the relevant expenses shall be borne by Party A. Party A shall be responsible for assisting and cooperating in relevant installation work and providing logistic and financial support for the life of relevant staff.

3.5 After the completion of the clinical trial, Party B shall be responsible for acquiring relevant certificates and licenses required for producing remedial chamber. Party B shall be responsible for ensuring relevant certificates and licenses to be attached to the remedial chamber equipment used for clinical cooperation after relevant certificates and licenses being obtained. In the event Party A requests to upgrade or transform the equipment, Party B shall provide support and assistance, and the relevant expenses shall be borne by Party A. Party A shall conduct independent management and clinical services under the guidance of Party B.

-6-

4. Intellectual Property and Confidentiality

4.1 The relevant intellectual property rights of the remedial chamber shall always belong to Party B, and Party A shall never infringe upon.

4.2 During project cooperation, staff from each party who get exposure to the equipment must sign a confidentiality agreement with Party B before entering the site to work. In the event the project cooperation is suspended or expired with no more cooperation, Party A shall have the right of use and disposal of the equipment invested during the cooperation on the premise of ensuring Party B’s intellectual property rights never being infringed.

5. Dispute Resolution

5.1 The law of the PRC shall be applicable to this Agreement.

-7-

5.2 Any dispute arising out of or in connection with performance of this Agreement shall be settled through negotiation, if no agreement is reached each Party has the right to initiate litigation in court of competent jurisdiction in Shenzhen.

6. Miscellaneous

6.1 This Agreement shall come into effect as of the date of the first sum of funds of one million and fifty thousand RMB (¥1,500,000) paid by Party A getting into the account designated by Party B.

6.2 Issues not covered in this Agreement shall be supplemented by both parties in written form. The supplementary agreements shall have the same legal effect as this Agreement.

6.3 Any other oral or written memorandum or agreement between Party A and Party B on this cooperation project shall be repealed, and this Agreement prevails.

-8-

6.4 This Agreement shall be written in Chinese and English versions. Whereas the Chinese and English versions are contradictory, the Chinese version shall prevail.

6.5 This Agreement is made in quadruplicate, with each Party holding two copies respectively, and each copy has the same legal effect.

(No text below)

-9-

(This page is only for the purpose of the signature of this Agreement)

Party A: Shenzhen Saikun Biotechnology Co., Ltd. (Seal)

Legal Representative: Chunjie Zhang

Date:

Party B: Jiashierle (Xiamen) Health Science & Technology Co., Ltd. (Seal)

Legal Representative: TAN HUNG SENG

Date:

Signed at:

_________________________________

-10-

EX-31.1 3 f10q0919ex31-1_heyubiologi.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ban Siong Ang, certify that:

1. I have reviewed this report on Form 10-Q of Heyu Biological Technology Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2019

/s/ Ban Siong Ang
Ban Siong Ang
Chairman of the Board of Directors, Chief Executive Officer, and President (Principal Executive Officer)

EX-31.2 4 f10q0919ex31-2_heyubiologi.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Wendy Wei Li, certify that:

1. I have reviewed this report on Form 10-Q of Heyu Biological Technology Corporation;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2019

/s/ Wendy Wei Li
Wendy Wei Li
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-32.1 5 f10q0919ex32-1_heyubiologi.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, in his capacity as an officer of Heyu Biological Technology Corporation (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Quarterly Report of the Company on Form 10-Q for the quarter ended September 30, 2019, (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2019

/s/ Ban Siong Ang
Ban Siong Ang
Chairman of the Board of Directors, Chief Executive Officer, and President (Principal Executive Officer and Director)

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

EX-32.2 6 f10q0919ex32-2_heyubiologi.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, in her capacity as an officer of Heyu Biological Technology Corporation (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 14, 2019

/s/ Wendy Wei Li
Wendy Wei Li
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-101.INS 7 hybt-20190930.xml XBRL INSTANCE FILE 0001086303 2019-01-01 2019-09-30 0001086303 2018-12-31 0001086303 2017-12-31 0001086303 2018-07-01 2018-09-30 0001086303 2018-01-01 2018-09-30 0001086303 hybt:SharePurchaseAgreementMember 2018-04-18 0001086303 2018-09-01 2018-09-11 0001086303 2018-09-30 0001086303 currency:CNY 2018-12-31 0001086303 hybt:SharePurchaseAgreementMember 2018-04-02 2018-04-18 0001086303 2018-04-01 2018-04-13 0001086303 us-gaap:CommonStockMember srt:MaximumMember 2018-09-11 0001086303 us-gaap:CommonStockMember srt:MinimumMember 2018-09-11 0001086303 hybt:HKMember 2019-01-01 2019-09-30 0001086303 country:CN 2019-01-01 2019-09-30 0001086303 2018-07-30 0001086303 hybt:BankDepositsChinaAndHKMember 2018-12-31 0001086303 hybt:HPTechnologyLimitedMember 2019-01-01 2019-09-30 0001086303 hybt:HeyuHealthcareTechnologyLimitedMember 2019-01-01 2019-09-30 0001086303 hybt:JSELMember 2019-01-01 2019-09-30 0001086303 hybt:KangziMember 2019-01-01 2019-09-30 0001086303 currency:CNY 2019-09-30 0001086303 hybt:ShanghaiKangziMedicalTechnologyCoLtdMember 2019-01-17 0001086303 hybt:JSELMember 2019-01-17 0001086303 2019-09-30 0001086303 hybt:BankDepositsChinaAndHKMember 2019-09-30 0001086303 hybt:FujianShanzhilingBiologicalTechnologyCoLtdMember 2018-10-02 2018-10-08 0001086303 hybt:ShareCancellationAgreementMember 2019-03-15 0001086303 2018-03-10 2018-03-12 0001086303 hybt:ShareCancellationAgreementMember 2018-10-30 0001086303 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2017-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2018-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001086303 us-gaap:CommonStockMember srt:ParentCompanyMember 2017-12-31 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2018-01-01 2018-09-30 0001086303 hybt:SharesToBeCancelledMember srt:ParentCompanyMember 2017-12-31 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001086303 us-gaap:AdditionalPaidInCapitalMember srt:ParentCompanyMember 2017-12-31 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ParentCompanyMember 2017-12-31 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001086303 us-gaap:RetainedEarningsMember srt:ParentCompanyMember 2017-12-31 0001086303 us-gaap:CommonStockMember srt:ParentCompanyMember 2019-01-01 2019-09-30 0001086303 us-gaap:CommonStockMember srt:ParentCompanyMember 2018-12-31 0001086303 us-gaap:CommonStockMember srt:ParentCompanyMember 2019-09-30 0001086303 hybt:SharesToBeCancelledMember srt:ParentCompanyMember 2019-01-01 2019-09-30 0001086303 hybt:SharesToBeCancelledMember srt:ParentCompanyMember 2018-12-31 0001086303 hybt:SharesToBeCancelledMember srt:ParentCompanyMember 2019-09-30 0001086303 us-gaap:AdditionalPaidInCapitalMember srt:ParentCompanyMember 2019-01-01 2019-09-30 0001086303 us-gaap:AdditionalPaidInCapitalMember srt:ParentCompanyMember 2018-12-31 0001086303 us-gaap:AdditionalPaidInCapitalMember srt:ParentCompanyMember 2019-09-30 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ParentCompanyMember 2019-01-01 2019-09-30 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ParentCompanyMember 2018-12-31 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember srt:ParentCompanyMember 2019-09-30 0001086303 us-gaap:RetainedEarningsMember srt:ParentCompanyMember 2019-01-01 2019-09-30 0001086303 us-gaap:RetainedEarningsMember srt:ParentCompanyMember 2018-12-31 0001086303 us-gaap:RetainedEarningsMember srt:ParentCompanyMember 2019-09-30 0001086303 hybt:FujianShanzhilingBiologicalMember 2019-09-30 0001086303 hybt:FujianShanzhilingBiologicalMember 2018-12-31 0001086303 hybt:OthersMember 2019-09-30 0001086303 hybt:OthersMember 2018-12-31 0001086303 hybt:FujianShanzhilingBiologicalTechnologyCoLtdMember 2019-01-01 2019-09-30 0001086303 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2019-09-30 0001086303 us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2018-12-31 0001086303 2019-07-01 2019-09-30 0001086303 srt:ParentCompanyMember us-gaap:CommonStockMember 2018-09-30 0001086303 srt:ParentCompanyMember hybt:SharesToBeCancelledMember 2018-09-30 0001086303 srt:ParentCompanyMember us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001086303 srt:ParentCompanyMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001086303 srt:ParentCompanyMember us-gaap:RetainedEarningsMember 2018-09-30 0001086303 us-gaap:NoncontrollingInterestMember 2018-09-30 0001086303 2019-09-01 0001086303 srt:OtherPropertyMember 2019-09-30 0001086303 srt:OtherPropertyMember 2018-12-31 0001086303 us-gaap:SubsequentEventMember 2019-10-01 2019-10-15 0001086303 2019-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

-357216

-125957

-147797

-38697

-147797

-357216

-184691

10-Q 2019-09-30 false Heyu Biological Technology Corp 0001086303 --12-31 Non-accelerated Filer true false false

0.001

2000000000

1141472861

1032466000

10324660

1032466000

109006861

1141472861

1032466000

10324660

1032466000

37555

452318

1021051700

150000000 2000000000

All common share amounts and per share amounts in the financial statements and disclosures have been presented giving effect to the 1-for-464 reverse split that became effective on April 11, 2018, and the 100-for-1 forward stock split that became effective on September 11, 2018.

The Nevada Secretary of State approved the Company's certificate of amendment to amend its Articles of Incorporation to effectuate a 100-for-1 forward stock split.

The Board of Directors, with the consent of the majority shareholder, voted for a 1-for-464 reverse stock split. On April 11, 2018 the reverse split became effective.

1000000000

6.8764

7.1360

7589

35633

9039

76085

335000

0.165

0.25

HP Technology Limited Heyu Healthcare Technology Limited JSEL Kangzi

British Virgin Islands

Hong Kong

The PRC

1.00

0.60

686579 Q3 2019 6.6146 6.8618

0.9891

0.90

0.60

0.51

301725

9409 Yes false 000-26731 Yes

21324

24566

21324

24566

24499

81431

1660239731

1032266000

636661604

1019289346

-0.00

0.00

-0.00

-342838

-125957

-147797

-173505

1546

1320

-341292

-125957

-147797

-172185

-15924

-12506

-38697

-20455

-395913

-125957

-147797

-205146

-395913

-125957

-147797

-205146

-1708

-370

-394205

-125957

-147797

-204776

419584

125957

147797

208497

412207

125957

202505

7377

5992

25379

3721

31938

3666

57317

7387

150642240

1141472861

1032466000

-237236

-54113

-139823

-620317

-40243

150642

17968787

-18173542

1141473

1032466

-109007

17149050

2567

16945

-18421319

-18778535

1032466

17149050

-18321339

-150317580

-150318 150318

32141340

32141 -32141 1000000000 10000 1000000 -990000 52087 52087

-109006861

-109007

109007

12832 -1546 14378 52087

10000

414763

12832

677945

157474

677945

157474

-276014

-157474

-1

95090

-9677

311134

-81431

3242

Basis of Presentation   The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.   The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2019 and 2018 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company as of September 30, 2019, the results of its operations for the three and nine months ended September 30, 2019 and 2018, and its cash flows for the nine months ended September 30, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2018 has been derived from the Company's audited financial statements included in the Form 10-K for the year ended December 31, 2018.   The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company's Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2018.    As of September 30, 2019, the details of the consolidating subsidiaries are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">Name of Company</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Place of incorporation</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center">The PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center">The PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr></table>

Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities.

Cash Equivalents   The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company's cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation ("FDIC") insurance or any other similar insurance in the PRC, or Hong Kong.

Inventories   Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Foreign Currency   For fiscal year 2019, the Company's principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company's subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders' equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarter ended September 30, 2019 and 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.1360</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8764</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">　 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate　</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8618</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.6146</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>   The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

General and administrative costs   General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes   The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain.   The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions.   The Company's policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure   The Company had 2,000,000,000 shares of authorized common stock, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2019, and 1,141,472,861 shares issued and outstanding as of December 31, 2018.

Earnings (loss) per share   Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive.   Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.   As of September 30, 2019 and December 31, 2018, there were no potentially dilutive shares.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Quarter Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(395,913</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(147,797</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average common shares outstanding - basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,660,239,731</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">636,661,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">Name of Company</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Place of incorporation</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center">The PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center">The PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.1360</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8764</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">　 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate　</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8618</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.6146</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Quarter Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(395,913</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(147,797</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average common shares outstanding - basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,660,239,731</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">636,661,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

NOTE 2 – GOING CONCERN   During the quarter ended September 30, 2019, the Company had been unable to generate cash flows sufficient to support its operations despite of Kangzi's business operation and had been dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $18,778,535 and working capital deficit of $686,579 as of September 30, 2019. These factors raise doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.   There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there would be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals.

NOTE 3 – CASH AND CASH EQUIVALENTS   Cash and cash equivalents consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Bank Deposits-China & HK</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">452,318</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">37,555</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">452,318</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">37,555</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

NOTE 4 – OTHER RECEIVABLE   Other receivable consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fujian Shanzhiling Biological Technology Co., Ltd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">　- 　</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">　 21,324 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; padding-bottom: 1.5pt">Others</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">24,566</td><td style="width: 1%; text-align: left; padding-bottom: 1.5pt"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="width: 1%; text-align: left; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">24,566</td><td style="text-align: left; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">21,324</td><td style="text-align: left; padding-bottom: 4pt"> </td></tr> </table>   On October 8, 2018, the Company entered into a non-binding letter of intent with Fujian Shanzhiling Biological Technology Co., Ltd. (the "Acquirer"), a Chinese biotechnology product manufacturing corporation, whereby the Acquirer agreed to acquire 51% of the outstanding capital of the Company subject to certain adjustment provisions (the "Shanzhiling Acquisition"). As of the date of this report, the Company has terminated the agreements related to Shanzhiling Acquisition; therefore, the related balance in the amount of $24,499 has been written off during the quarter ended September 30, 2019. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fujian Shanzhiling Biological Technology Co., Ltd.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">　- 　</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">　 21,324 </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 76%; padding-bottom: 1.5pt">Others</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">24,566</td><td style="width: 1%; text-align: left; padding-bottom: 1.5pt"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"> </td><td style="width: 9%; text-align: right; border-bottom: Black 1.5pt solid">-</td><td style="width: 1%; text-align: left; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">24,566</td><td style="text-align: left; padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: left; border-bottom: Black 4pt double">$</td><td style="text-align: right; border-bottom: Black 4pt double">21,324</td><td style="text-align: left; padding-bottom: 4pt"> </td></tr> </table> NOTE 5 – ADVANCES TO SUPPLIERS   Advances to suppliers consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Prepayment for purchase of raw materials</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">81,431</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">81,431</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">  0</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Prepayment for purchase of raw materials</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">81,431</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">81,431</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">  0</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">301,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">311,134</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">   -</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

NOTE 11 – EQUITY   The Company recorded the following equity transactions during the nine months ended September 30, 2019:   On March 15, 2019, the Company, with the approval of the Board, entered into a Share Cancellation Agreement (the "Share Cancellation Agreement") with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of the Company. Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of Common Stock previously issued to Mr. Ang.   The Company recorded the following equity transactions during the year ended December 31, 2018:   On March 12, 2018, the Board of Directors, with the consent of the majority shareholder, voted for a 1-for-464 reverse stock split. On April 11, 2018 the reverse split became effective.   On April 13, 2018, 1,000,000,000 shares were issued to a prior related party as a repayment of debt.   On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of Common Stock from Mr. Masters for an aggregate purchase price of $335,000. As a result of the Share Purchase Agreement, the Company accepted the resignation of Mr. Masters, as the Company's President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.   On July 30, 2018, the Company amended its Articles of Incorporation with the State of Nevada in order to increase its authorized shares of Common Stock from 150,000,000 to 2,000,000,000.   On September 11, 2018, the Nevada Secretary of State approved the Company's certificate of amendment to amend its Articles of Incorporation to effectuate a 100-for-1 forward stock split. The total issued and outstanding shares of Common Stock has been increased from 10,324,660 to 1,032,466,000 shares, with the par value unchanged at $0.001.   In October 2018, the controlling stockholder of the Company, Mr. Ban Siong Ang, entered into a series of share transfer agreements (the "Share Transfer Agreements") with certain buyers (the "Buyers"). Pursuant to the Share Transfer Agreements, an aggregate of 109,006,861 shares of Common Stock were issued to the Buyers, but the cancellation of the 109,006,861 shares of Common Stock held by Mr. Ang was still in process as of December 31, 2018. The cancellation of those shares held by Mr. Ang was subsequently completed on March 20, 2019, pursuant to a Share Cancellation Agreement dated March 15, 2019, by and between the Company and Mr. Ang.   Unless otherwise indicated, all common share amounts and per share amounts in the financial statements and disclosures have been presented giving effect to the 1-for-464 reverse split that became effective on April 11, 2018, and the 100-for-1 forward stock split that became effective on September 11, 2018.

NOTE 12 – INCOME TAXES   The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States.   Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong.   The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

Leases   The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements.   Operating leases are included in operating lease right-of-use ("ROU") assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.   ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.   Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.    ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table>    The approximate future minimum lease payments under operating leases as:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fiscal 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,304</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">215,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fiscal 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,304</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">215,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

P3Y0M0D

0.0475

25409

77074

79615

54206

236304

21005

215298

209587

215298

209587

209798

215298

-18421319

-18778535

311134

16628

111718

66473

143325

279464

957409

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(66,473</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">     -</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(209,798</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

209587

58879

1079036

-40243

-237236

-580074

2567

16945

17149050

109007

1141473

1032466

296115

1699353

143325

296115

1556028

58879

1079036

58879

869449

81431

209798

420406

209587 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr></table>

NOTE 6 – INVENTORY   Inventory consists of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">301,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,409</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">311,134</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">   -</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    No impairment was provided for the inventories as of September 30, 2019.

NOTE 7 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES   As of September 1, 2019, company entered in lease agreement for the office space, the right-of-use asset is recognized as following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">209,587</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">  -</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">209,587</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Operating lease liability consist both current and noncurrent component as the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(66,473</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">     -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(209,798</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term (Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table>    The approximate future minimum lease payments under operating leases as:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fiscal 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,304</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">215,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As of September 30, 2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As of December 31, 2018</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%">Operating lease right-of-use asset</td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right">209,587</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right">  -</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">209,587</td> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">-</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As of September 30, 2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As of December 31, 2018</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%">Operating lease liability - current portion</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">(66,473</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">     -</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Operating lease liability</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(143,325</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">(209,798</td> <td>)</td> <td> </td> <td style="border-bottom: black 4.5pt double">$</td> <td style="border-bottom: black 4.5pt double; text-align: right">-</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">September 1, 2019</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%">Weighted Average Remaining Lease Term (Year)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">3</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted Average Discount Rate</td> <td> </td> <td> </td> <td style="text-align: right">4.75</td> <td>% </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fiscal 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,304</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">215,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

25409

21005

NOTE 8 – ADVANCES FROM CUSTOMERS    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Advances from customers(1)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">420,406</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">     -</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">420,406</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">(1)</td> <td style="text-align: justify">On October 15 2019, JSEL entered into a clinical cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. </td></tr></table>

420406

NOTE 9 – ACCRUED EXPENSES AND OTHER PAYABLES   Accrued expenses and other payables consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued payroll</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">35,633</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,589</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other Payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,085</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,039</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111,718</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,628</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>   Accrued payroll includes all company employee payroll liabilities as of September 30, 2019, and other payables contains employee reimbursements.   Operating lease liability consist both current and noncurrent component as the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">(66,473</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(143,325</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">     -</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(209,798</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued payroll</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">35,633</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7,589</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other Payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,085</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,039</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">111,718</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,628</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

JSEL entered into a clinical cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. 1032466000

NOTE 10 – RELATED PARTY TRANSACTIONS   As of September 30, 2019, and December 31, 2018, the Company owed related parties $957,409 and $279,464, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by a related party. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls.   A director of the Company provides the property for the use by the Company without charge.

215298

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES   Heyu Biological Technology Corporation (the "Company") was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016 the Company proposed a Plan of Liquidation and on November 28, 2016, the Court entered an order confirming the Plan of Liquidation and establishing a Liquidating Trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the Liquidating Trust.   On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company ("Common Stock") from Mr. Masters for an aggregate purchase price of $335,000 (the "Share Purchase"). As a result of the Share Purchase Agreement, the Company accepted the resignation of Dan Masters, as the Company's President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.   On April 18, 2018, to fill the vacancies created by Mr. Masters's resignations, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board. Mr. Tan was appointed as Executive Director of the Company. Ms. Wendy Wei Li was appointed as Chief Financial Officer.   On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation, with a new ticker symbol, HYBT.   During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018 and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. Further, on November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. ("JSEL"), a limited liability company incorporated under the laws of the People's Republic of China (the "PRC") on November 16, 2017.   On January 17, 2019, JSEL entered into a Share Transfer Agreement (the "Share Transfer Agreement") with Mr. Yu Xu ("Mr. Xu"), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC, and who owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC ("Kangzi"). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in the business of selling medical equipment. It was the parties' intention that JSEL would fund the operations of Kangzi in proportion to its equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation of its own.   In March 2019, the Company entered into a Raspberry Purchase Agreement and a Raspberry Juice Processing Agreement with Luoyang Ditiantai Agricultural Development Co., Ltd. ("Ditiantai"). Pursuant to these two agreements, the Company purchased six tons of raspberry from Ditiantai, which were processed by Ditiantai into raspberry juice and delivered to the Company. The Company then sold the raspberry juice to a corporate buyer and five individual buyers. The Company, however, does not plan to engage in the business of selling raspberry juice in the long term.   Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the "Chamber"). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Specifically, we believe that exposure to an appropriate amount of submillimeter waves could accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancering process through which selenium is converted into nickel inside cells.   The team consists of researchers whom have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, as the chairman and chief scientist of Shanghai Guangcon New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu was rewarded the "Harmony-Person of the Year in China" at the "2011 Harmony China Annual Summit" in Beijing and recognized as "Leaping China: One of the Most Influential People of the Year in 2011" by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of Boau Forum on Asian SME Development awarded Mr. Xu "2013 China Economic Outstanding Contribution Award."   Pursuant to the terms of the Share Transfer Agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for the Chamber in September.   Basis of Presentation   The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.   The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2019 and 2018 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company as of September 30, 2019, the results of its operations for the three and nine months ended September 30, 2019 and 2018, and its cash flows for the nine months ended September 30, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2018 has been derived from the Company's audited financial statements included in the Form 10-K for the year ended December 31, 2018.   The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company's Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2018.    As of September 30, 2019, the details of the consolidating subsidiaries are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">Name of Company</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Place of incorporation</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1.5pt solid">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 67%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 20%; text-align: center">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center">The PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center">The PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table>   Use of Estimates   The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities.   Cash Equivalents   The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company's cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation ("FDIC") insurance or any other similar insurance in the PRC, or Hong Kong.   Inventories   Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.   Leases   The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements.   Operating leases are included in operating lease right-of-use ("ROU") assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.   ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.   Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.    ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">September 1, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Weighted Average Remaining Lease Term(Year)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted Average Discount Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.75</td><td style="text-align: left">%</td></tr> </table>    The approximate future minimum lease payments under operating leases as:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating Leases</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%">Fiscal 2019</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">25,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Fiscal 2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,074</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fiscal 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,615</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Fiscal 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in">Total Lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">236,304</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,005</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; padding-left: 0.125in">Present value of lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">215,298</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>     Foreign Currency   For fiscal year 2019, the Company's principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company's subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders' equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarter ended September 30, 2019 and 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.1360</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8764</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">　 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate　</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8618</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.6146</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>   The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.   General and administrative costs   General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.   Income Taxes   The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain.   The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions.   The Company's policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.   Capital Structure   The Company had 2,000,000,000 shares of authorized common stock, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2019, and 1,141,472,861 shares issued and outstanding as of December 31, 2018.   Earnings (loss) per share   Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive.   Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.   As of September 30, 2019 and December 31, 2018, there were no potentially dilutive shares.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">For the Quarter Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(395,913</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(147,797</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Weighted-average common shares outstanding - basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,660,239,731</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">636,661,604</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr></table>

On October 15 2019, JSEL entered into a clinical cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

EX-101.SCH 8 hybt-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - The Company and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Cash and Cash Equivalents link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Other Receivable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Advances to Suppliers link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Advances from Customers link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Accrued Expenses and Other Payables link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - The Company and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - The Company and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Other Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Advances to Suppliers (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Advances from Customers (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accrued Expenses and Other Payables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - The Company and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - The Company and Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - The Company and Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - The Company and Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - The Company and Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - The Company and Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Other Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Other Receivable (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Advances to Suppliers (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Advances from Customers (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Advances from Customers (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Accrued Expenses and Other Payables (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Accrued Expenses and Other Payables (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 hybt-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 hybt-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 hybt-20190930_lab.xml XBRL LABEL FILE Business Acquisition [Axis] Share Purchase Agreement [Member] Currency [Axis] RMB [Member] Equity Components [Axis] Common Stock [Member] Range [Axis] Maximum [Member] Minimum [Member] Geographical [Axis] HONG KONG [Member] CHINA [Member] Bank Deposits-China & HK [Member] Ownership [Axis] HP Technology Limited [Member] Heyu Healthcare Technology Limited [Member] JSEL [Member] Kangzi [Member] Shanghai Kangzi Medical Technology Co Limited [Member] Fujian Shanzhiling Biological Technology Co., Ltd [Member] Share Cancellation Agreement [Member] Noncontrolling Interest Consolidated Entities [Axis] Parent Company [Member] Shares to be cancelled Additional Paid-In Capital Other Comprehensive Income / Loss Retained Earnings / Accumulated Deficit Fujian Shanzhiling Biological [Axis] Fujian Shanzhiling Biological [Member] Others [Member] Inventory [Axis] Raw Materials [Member] Real Estate, Type of Property [Axis] Other Property [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity Filer Category Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity File Number Entity Interactive Data Current Entity Incorporation State Country Code Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Other receivables Advances to suppliers Inventory Total current assets Non-current Assets Operating lease right-of-use asset Total non-current assets Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued expenses Advances from customers Income tax and other taxes payable Operating lease liability - current portion Related party payables Total current liabilities Noncurrent liabilities Operating lease liability Total noncurrent liabilities Total Liabilities Stockholders' Deficit Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 and 1,141,472,861 shares issued and outstanding respectively as of September 30, 2019 and December 31, 2018, respectively) Shares to be cancelled Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Stockholders' equity - HYBT and Subsidiaries Noncontrolling interests in subsidiaries Total stockholders' deficit Total Liabilities and Stockholders' Deficit Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue, net Cost of Revenue Gross Profit Operating expenses Selling expenses Administrative expenses Total operating expenses Loss on operations Other Income(Expenses) Loss on operations before income taxes Income tax expense Net Loss Loss attributable to noncontrolling interests Net loss attributable to HYBT shareholders Other Comprehensive Income Foreign currency translation adjustment Total Comprehensive Loss Total comprehensive income attributable to noncontrolling interests Total comprehensive loss attributable to HYBT shareholders Net loss per share - basic and diluted Weighted average shares - basic and diluted Statement [Table] Statement [Line Items] Heyu Biological Shareholders’ Equity Common Stock Additional Paid in Capital Accumulated Other Comprehensive Income Accumulated Deficit Non - controlling Interest Balance Balance, shares 1 for 464 reverse split 1 for 464 reverse split, shares 1 for 100 split 1 for 100 split, shares Common stock issued April 13, 2018 Common stock issued April 13, 2018, shares Waiver of payable to ex-shareholder Shares cancelled March 20, 2019 Shares cancelled March 20, 2019, shares Foreign currency translation adjustment Loss for the period Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Loss Adjustments to reconcile net loss to net cash used in operating activities: Change in assets and liabilities Other receivables Advances to suppliers Inventory Operating lease right-of-use asset Accounts payable and accrued liabilities Advances from customers Income tax and other taxes payable Lease liability Net cash used from operating activities CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from related party lending Net cash used in financing activities Effect of exchange rate changes on cash NET INCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid for interest Cash paid for income tax Non-cash activities Shares issued for repayment of debt Related party forgiveness of debt Accounting Policies [Abstract] THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES Going Concern [Abstract] GOING CONCERN Cash and Cash Equivalents [Abstract] CASH AND CASH EQUIVALENTS Other Receivable [Abstract] OTHER RECEIVABLE Advances to Suppliers [Abstract] ADVANCES TO SUPPLIERS Inventory Disclosure [Abstract] INVENTORY Leases [Abstract] Operating Lease Right-of-Use Asset and Liabilities Advances from Customers [Abstract] ADVANCES FROM CUSTOMERS Payables and Accruals [Abstract] ACCRUED EXPENSES AND OTHER PAYABLES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] EQUITY Income Tax Disclosure [Abstract] INCOME TAXES Basis of Presentation Use of Estimates Cash Equivalents Inventories Leases Foreign Currency EX-101.PRE 12 hybt-20190930_pre.xml XBRL PRESENTATION FILE XML 13 R34.htm IDEA: XBRL DOCUMENT

Going Concern (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Going Concern (Textual)
Accumulated deficit	$ (18,778,535)	$ (18,421,319)
Working capital deficit	$ 686,579

XML 14 R30.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details 2)	Sep. 30, 2019 USD ($)
Accounting Policies [Abstract]
Fiscal 2019	$ 25,409
Fiscal 2020	77,074
Fiscal 2021	79,615
Fiscal 2022	54,206
Total Lease payments	236,304
Less Imputed interest	21,005
Present value of lease liabilities	$ 215,298

XML 15 R38.htm IDEA: XBRL DOCUMENT

Advances to Suppliers (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Prepayment for purchase of raw materials	$ 81,431
Raw Materials [Member]
Prepayment for purchase of raw materials	$ 81,431

XML 16 R13.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Operating Lease Right-of-Use Asset and Liabilities

NOTE 7 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

As of September 1, 2019, company entered in lease agreement for the office space, the right-of-use asset is recognized as following:

	As of September 30, 2019		As of December 31, 2018

Operating lease right-of-use asset		209,587		-
	$	209,587	$	-

Operating lease liability consist both current and noncurrent component as the following:

	As of September 30, 2019			As of December 31, 2018

Operating lease liability - current portion		(66,473	)		-
Operating lease liability		(143,325	)		-
	$	(209,798	)	$	-

	September 1, 2019
Weighted Average Remaining Lease Term (Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2019		25,409
Fiscal 2020		77,074
Fiscal 2021		79,615
Fiscal 2022		54,206
Total Lease payments		236,304
Less Imputed interest		21,005
Present value of lease liabilities	$	215,298

XML 17 R17.htm IDEA: XBRL DOCUMENT

Equity

9 Months Ended

Sep. 30, 2019

Equity [Abstract]

EQUITY

NOTE 11 – EQUITY

The Company recorded the following equity transactions during the nine months ended September 30, 2019:

On March 15, 2019, the Company, with the approval of the Board, entered into a Share Cancellation Agreement (the "Share Cancellation Agreement") with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of the Company. Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of Common Stock previously issued to Mr. Ang.

The Company recorded the following equity transactions during the year ended December 31, 2018:

On March 12, 2018, the Board of Directors, with the consent of the majority shareholder, voted for a 1-for-464 reverse stock split. On April 11, 2018 the reverse split became effective.

On April 13, 2018, 1,000,000,000 shares were issued to a prior related party as a repayment of debt.

On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of Common Stock from Mr. Masters for an aggregate purchase price of $335,000. As a result of the Share Purchase Agreement, the Company accepted the resignation of Mr. Masters, as the Company's President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On July 30, 2018, the Company amended its Articles of Incorporation with the State of Nevada in order to increase its authorized shares of Common Stock from 150,000,000 to 2,000,000,000.

On September 11, 2018, the Nevada Secretary of State approved the Company's certificate of amendment to amend its Articles of Incorporation to effectuate a 100-for-1 forward stock split. The total issued and outstanding shares of Common Stock has been increased from 10,324,660 to 1,032,466,000 shares, with the par value unchanged at $0.001.

In October 2018, the controlling stockholder of the Company, Mr. Ban Siong Ang, entered into a series of share transfer agreements (the "Share Transfer Agreements") with certain buyers (the "Buyers"). Pursuant to the Share Transfer Agreements, an aggregate of 109,006,861 shares of Common Stock were issued to the Buyers, but the cancellation of the 109,006,861 shares of Common Stock held by Mr. Ang was still in process as of December 31, 2018. The cancellation of those shares held by Mr. Ang was subsequently completed on March 20, 2019, pursuant to a Share Cancellation Agreement dated March 15, 2019, by and between the Company and Mr. Ang.

XML 18 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 19 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,032,466,000	1,141,472,861
Common stock, shares outstanding	1,032,466,000	1,141,472,861

XML 20 R7.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

Heyu Biological Technology Corporation (the "Company") was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016 the Company proposed a Plan of Liquidation and on November 28, 2016, the Court entered an order confirming the Plan of Liquidation and establishing a Liquidating Trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the Liquidating Trust.

On April 18, 2018, the Company entered into a Share Purchase Agreement with Mr. Ban Siong Ang and Mr. Dan Masters, pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company ("Common Stock") from Mr. Masters for an aggregate purchase price of $335,000 (the "Share Purchase"). As a result of the Share Purchase Agreement, the Company accepted the resignation of Dan Masters, as the Company's President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On April 18, 2018, to fill the vacancies created by Mr. Masters's resignations, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board. Mr. Tan was appointed as Executive Director of the Company. Ms. Wendy Wei Li was appointed as Chief Financial Officer.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation, with a new ticker symbol, HYBT.

During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018 and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. Further, on November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. ("JSEL"), a limited liability company incorporated under the laws of the People's Republic of China (the "PRC") on November 16, 2017.

On January 17, 2019, JSEL entered into a Share Transfer Agreement (the "Share Transfer Agreement") with Mr. Yu Xu ("Mr. Xu"), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC, and who owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC ("Kangzi"). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in the business of selling medical equipment. It was the parties' intention that JSEL would fund the operations of Kangzi in proportion to its equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation of its own.

In March 2019, the Company entered into a Raspberry Purchase Agreement and a Raspberry Juice Processing Agreement with Luoyang Ditiantai Agricultural Development Co., Ltd. ("Ditiantai"). Pursuant to these two agreements, the Company purchased six tons of raspberry from Ditiantai, which were processed by Ditiantai into raspberry juice and delivered to the Company. The Company then sold the raspberry juice to a corporate buyer and five individual buyers. The Company, however, does not plan to engage in the business of selling raspberry juice in the long term.

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the "Chamber"). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Specifically, we believe that exposure to an appropriate amount of submillimeter waves could accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancering process through which selenium is converted into nickel inside cells.

The team consists of researchers whom have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, as the chairman and chief scientist of Shanghai Guangcon New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu was rewarded the "Harmony-Person of the Year in China" at the "2011 Harmony China Annual Summit" in Beijing and recognized as "Leaping China: One of the Most Influential People of the Year in 2011" by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of Boau Forum on Asian SME Development awarded Mr. Xu "2013 China Economic Outstanding Contribution Award."

Basis of Presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2019 and 2018 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company as of September 30, 2019, the results of its operations for the three and nine months ended September 30, 2019 and 2018, and its cash flows for the nine months ended September 30, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2018 has been derived from the Company's audited financial statements included in the Form 10-K for the year ended December 31, 2018.

The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company's Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2018.

As of September 30, 2019, the details of the consolidating subsidiaries are as follows:

Name of Company	Place of incorporation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	The PRC		100	%

Kangzi	The PRC		60	%

Use of Estimates

Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company's cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation ("FDIC") insurance or any other similar insurance in the PRC, or Hong Kong.

Inventories

Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Leases

Operating leases are included in operating lease right-of-use ("ROU") assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

The approximate future minimum lease payments under operating leases as:

	Operating Leases
Fiscal 2019		25,409
Fiscal 2020		77,074
Fiscal 2021		79,615
Fiscal 2022		54,206
Total Lease payments		236,304
Less Imputed interest		21,005
Present value of lease liabilities	$	215,298

Foreign Currency

For fiscal year 2019, the Company's principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company's subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders' equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarter ended September 30, 2019 and 2018.

	As of
	September 30, 2019		December 31, 2018
RMB: US$ exchange rate		7.1360		6.8764

	Nine months ended September 30,
	2019		2018
RMB: US$ exchange rate		6.8618		6.6146

General and administrative costs

Income Taxes

The Company's policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

Earnings (loss) per share

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

As of September 30, 2019 and December 31, 2018, there were no potentially dilutive shares.

	For the Quarter Ended September 30,
	2019			2018
Statement of Operations Summary Information:
Net loss	$	(395,913	)	$	(147,797	)
Weighted-average common shares outstanding - basic and diluted		1,660,239,731			636,661,604
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 21 R44.htm IDEA: XBRL DOCUMENT

Advances from Customers (Details Textual)

Oct. 15, 2019

Subsequent Event [Member]

Advances from customers,description

XML 22 R40.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - USD ($)	Sep. 30, 2019	Sep. 01, 2019
Operating lease right-of-use asset	$ 209,587	$ 215,298
Office space [Member]
Operating lease right-of-use asset	$ 209,587

XML 23 R48.htm IDEA: XBRL DOCUMENT

Equity (Details) - USD ($)				1 Months Ended	9 Months Ended
Equity (Details) - USD ($)	Sep. 11, 2018	Apr. 13, 2018	Mar. 12, 2018	Apr. 18, 2018	Sep. 30, 2019	Mar. 15, 2019	Dec. 31, 2018	Oct. 30, 2018	Jul. 30, 2018
Equity (Textual)
Increase authorized shares of common stock shares minimum									150,000,000
Increase authorized shares of common stock shares maximum									2,000,000,000
Reverse split, description	The Nevada Secretary of State approved the Company's certificate of amendment to amend its Articles of Incorporation to effectuate a 100-for-1 forward stock split.		The Board of Directors, with the consent of the majority shareholder, voted for a 1-for-464 reverse stock split. On April 11, 2018 the reverse split became effective.		All common share amounts and per share amounts in the financial statements and disclosures have been presented giving effect to the 1-for-464 reverse split that became effective on April 11, 2018, and the 100-for-1 forward stock split that became effective on September 11, 2018.
Shares of common stock in exchange for reduction in related party payable		1,000,000,000
Par value of common stock					$ 0.001		$ 0.001
Common stock, shares issued					1,032,466,000		1,141,472,861
Common stock, shares outstanding					1,032,466,000		1,141,472,861
Common Stock [Member] \| Minimum [Member]
Equity (Textual)
Par value of common stock	$ 0.001
Common stock, shares issued	10,324,660
Common stock, shares outstanding	10,324,660
Common Stock [Member] \| Maximum [Member]
Equity (Textual)
Par value of common stock	$ 0.001
Common stock, shares issued	1,032,466,000
Common stock, shares outstanding	1,032,466,000
Share Cancellation Agreement [Member]
Equity (Textual)
Common stock, shares issued						109,006,861		109,006,861
Share Purchase Agreement [Member]
Equity (Textual)
Purchaser acquired shares				1,021,051,700
Purchaser acquired shares percentage				98.91%
Aggregate purchase price				$ 335,000

XML 24 R29.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details 1)	Sep. 01, 2019
Accounting Policies [Abstract]
Weighted Average Remaining Lease Term(Year)	3 years
Weighted Average Discount Rate	4.75%

XML 25 R21.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Tables)

9 Months Ended

Sep. 30, 2019

Cash and Cash Equivalents [Abstract]

Schedule of cash and cash equivalents

	As of September 30, 2019		As of December 31, 2018

Bank Deposits-China & HK		452,318		37,555
	$	452,318	$	37,555

XML 26 R25.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of right-of-use asset

	As of September 30, 2019		As of December 31, 2018

Operating lease right-of-use asset		209,587		-
	$	209,587	$	-

	As of September 30, 2019			As of December 31, 2018

Operating lease liability - current portion		(66,473	)		-
Operating lease liability		(143,325	)		-
	$	(209,798	)	$	-

	September 1, 2019
Weighted Average Remaining Lease Term (Year)		3
Weighted Average Discount Rate		4.75	%

Schedule of maturities of lease liabilities

	Operating Leases
Fiscal 2019		25,409
Fiscal 2020		77,074
Fiscal 2021		79,615
Fiscal 2022		54,206
Total Lease payments		236,304
Less Imputed interest		21,005
Present value of lease liabilities	$	215,298

XML 27 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 79 248 1 true 26 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://heyu.com/20180630/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://heyu.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://heyu.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://heyu.com/role/StatementsOfOperationsAndComprehensiveIncome Consolidated Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders??? Deficit (Unaudited) Sheet http://heyu.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders??? Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://heyu.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - The Company and Significant Accounting Policies Sheet http://heyu.com/role/CompanyAndSignificantAccountingPolicies The Company and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://heyu.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Cash and Cash Equivalents Sheet http://heyu.com/role/CashAndCashEquivalents Cash and Cash Equivalents Notes 9 false false R10.htm 00000010 - Disclosure - Other Receivable Sheet http://heyu.com/role/OtherReceivable Other Receivable Notes 10 false false R11.htm 00000011 - Disclosure - Advances to Suppliers Sheet http://heyu.com/role/AdvancesToSuppliers Advances to Suppliers Notes 11 false false R12.htm 00000012 - Disclosure - Inventory Sheet http://heyu.com/role/Inventory Inventory Notes 12 false false R13.htm 00000013 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities Sheet http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilities Operating Lease Right-of-Use Asset and Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Advances from Customers Sheet http://heyu.com/role/AdvancesFromCustomers Advances from Customers Notes 14 false false R15.htm 00000015 - Disclosure - Accrued Expenses and Other Payables Sheet http://heyu.com/role/AccruedExpensesAndOtherPayables Accrued Expenses and Other Payables Notes 15 false false R16.htm 00000016 - Disclosure - Related Party Transactions Sheet http://heyu.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Equity Sheet http://heyu.com/role/Equity Equity Notes 17 false false R18.htm 00000018 - Disclosure - Income Taxes Sheet http://heyu.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 00000019 - Disclosure - The Company and Significant Accounting Policies (Policies) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesPolicies The Company and Significant Accounting Policies (Policies) Policies http://heyu.com/role/CompanyAndSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - The Company and Significant Accounting Policies (Tables) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables The Company and Significant Accounting Policies (Tables) Tables http://heyu.com/role/CompanyAndSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://heyu.com/role/CashAndCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://heyu.com/role/CashAndCashEquivalents 21 false false R22.htm 00000022 - Disclosure - Other Receivable (Tables) Sheet http://heyu.com/role/OtherReceivableTables Other Receivable (Tables) Tables http://heyu.com/role/OtherReceivable 22 false false R23.htm 00000023 - Disclosure - Advances to Suppliers (Tables) Sheet http://heyu.com/role/AdvancesToSuppliersTables Advances to Suppliers (Tables) Tables http://heyu.com/role/AdvancesToSuppliers 23 false false R24.htm 00000024 - Disclosure - Inventory (Tables) Sheet http://heyu.com/role/InventoryTables Inventory (Tables) Tables http://heyu.com/role/Inventory 24 false false R25.htm 00000025 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables) Sheet http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesTables Operating Lease Right-of-Use Asset and Liabilities (Tables) Tables http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilities 25 false false R26.htm 00000026 - Disclosure - Advances from Customers (Tables) Sheet http://heyu.com/role/AdvancesFromCustomersTables Advances from Customers (Tables) Tables http://heyu.com/role/AdvancesFromCustomers 26 false false R27.htm 00000027 - Disclosure - Accrued Expenses and Other Payables (Tables) Sheet http://heyu.com/role/AccruedExpensesAndOtherPayablesTables Accrued Expenses and Other Payables (Tables) Tables http://heyu.com/role/AccruedExpensesAndOtherPayables 27 false false R28.htm 00000028 - Disclosure - The Company and Significant Accounting Policies (Details) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesDetails The Company and Significant Accounting Policies (Details) Details http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - The Company and Significant Accounting Policies (Details 1) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesDetails1 The Company and Significant Accounting Policies (Details 1) Details http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - The Company and Significant Accounting Policies (Details 2) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesDetails2 The Company and Significant Accounting Policies (Details 2) Details http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables 30 false false R31.htm 00000031 - Disclosure - The Company and Significant Accounting Policies (Details 3) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesDetails3 The Company and Significant Accounting Policies (Details 3) Details http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables 31 false false R32.htm 00000032 - Disclosure - The Company and Significant Accounting Policies (Details 4) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesDetails4 The Company and Significant Accounting Policies (Details 4) Details http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - The Company and Significant Accounting Policies (Details Textual) Sheet http://heyu.com/role/CompanyAndSignificantAccountingPoliciesDetailsTextual The Company and Significant Accounting Policies (Details Textual) Details http://heyu.com/role/CompanyAndSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - Going Concern (Details) Sheet http://heyu.com/role/GoingConcernDetails Going Concern (Details) Details http://heyu.com/role/GoingConcern 34 false false R35.htm 00000035 - Disclosure - Cash and Cash Equivalents (Details) Sheet http://heyu.com/role/CashAndCashEquivalentsDetails Cash and Cash Equivalents (Details) Details http://heyu.com/role/CashAndCashEquivalentsTables 35 false false R36.htm 00000036 - Disclosure - Other Receivable (Details) Sheet http://heyu.com/role/OtherReceivableDetails Other Receivable (Details) Details http://heyu.com/role/OtherReceivableTables 36 false false R37.htm 00000037 - Disclosure - Other Receivable (Details Textual) Sheet http://heyu.com/role/OtherReceivableDetailsTextual Other Receivable (Details Textual) Details http://heyu.com/role/OtherReceivableTables 37 false false R38.htm 00000038 - Disclosure - Advances to Suppliers (Details) Sheet http://heyu.com/role/AdvancesToSuppliersDetails Advances to Suppliers (Details) Details http://heyu.com/role/AdvancesToSuppliersTables 38 false false R39.htm 00000039 - Disclosure - Inventory (Details) Sheet http://heyu.com/role/InventoryDetails Inventory (Details) Details http://heyu.com/role/InventoryTables 39 false false R40.htm 00000040 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) Sheet http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesDetails Operating Lease Right-of-Use Asset and Liabilities (Details) Details http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesTables 40 false false R41.htm 00000041 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details 1) Sheet http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesDetails1 Operating Lease Right-of-Use Asset and Liabilities (Details 1) Details http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesTables 41 false false R42.htm 00000042 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details 2) Sheet http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesDetails2 Operating Lease Right-of-Use Asset and Liabilities (Details 2) Details http://heyu.com/role/OperatingLeaseRight-of-useAssetAndLiabilitiesTables 42 false false R43.htm 00000043 - Disclosure - Advances from Customers (Details) Sheet http://heyu.com/role/AdvancesFromCustomersDetails Advances from Customers (Details) Details http://heyu.com/role/AdvancesFromCustomersTables 43 false false R44.htm 00000044 - Disclosure - Advances from Customers (Details Textual) Sheet http://heyu.com/role/AdvancesFromCustomersDetailsTextual Advances from Customers (Details Textual) Details http://heyu.com/role/AdvancesFromCustomersTables 44 false false R45.htm 00000045 - Disclosure - Accrued Expenses and Other Payables (Details) Sheet http://heyu.com/role/AccruedExpensesAndOtherPayablesDetails Accrued Expenses and Other Payables (Details) Details http://heyu.com/role/AccruedExpensesAndOtherPayablesTables 45 false false R46.htm 00000046 - Disclosure - Accrued Expenses and Other Payables (Details 1) Sheet http://heyu.com/role/AccruedExpensesAndOtherPayablesDetails1 Accrued Expenses and Other Payables (Details 1) Details http://heyu.com/role/AccruedExpensesAndOtherPayablesTables 46 false false R47.htm 00000047 - Disclosure - Related Party Transactions (Details) Sheet http://heyu.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://heyu.com/role/RelatedPartyTransactions 47 false false R48.htm 00000048 - Disclosure - Equity (Details) Sheet http://heyu.com/role/EquityDetails Equity (Details) Details http://heyu.com/role/Equity 48 false false R49.htm 00000049 - Disclosure - Income Taxes (Details) Sheet http://heyu.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://heyu.com/role/IncomeTaxes 49 false false All Reports Book All Reports hybt-20190930.xml hybt-20190930.xsd hybt-20190930_cal.xml hybt-20190930_def.xml hybt-20190930_lab.xml hybt-20190930_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/currency/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 28 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Current Assets

Cash and cash equivalents

$ 452,318

$ 37,555

Other receivables

24,566

21,324

Advances to suppliers

81,431

Inventory

311,134

Total current assets

869,449

58,879

Non-current Assets

Operating lease right-of-use asset

209,587

Total non-current assets

209,587

Total Assets

1,079,036

58,879

Current Liabilities

Accounts payable and accrued expenses

111,718

16,628

Advances from customers

^[1]

420,406

Income tax and other taxes payable

Operating lease liability - current portion

66,473

Related party payables

957,409

279,464

Total current liabilities

1,556,028

296,115

Noncurrent liabilities

Operating lease liability

143,325

Total noncurrent liabilities

143,325

Total Liabilities

1,699,353

296,115

Stockholders' Deficit

Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 and 1,141,472,861 shares issued and outstanding respectively as of September 30, 2019 and December 31, 2018, respectively)

1,032,466

1,141,473

Shares to be cancelled

(109,007)

Additional paid-in capital

17,149,050

Accumulated other comprehensive income

16,945

2,567

Accumulated deficit

(18,778,535)

(18,421,319)

Stockholders' equity - HYBT and Subsidiaries

(580,074)

(237,236)

Noncontrolling interests in subsidiaries

(40,243)

Total stockholders' deficit

(620,317)

(237,236)

Total Liabilities and Stockholders' Deficit

$ 1,079,036

$ 58,879

[1]

XML 29 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (395,913)	$ (147,797)
Change in assets and liabilities
Other receivables	(3,242)
Advances to suppliers	(81,431)
Inventory	(311,134)
Operating lease right-of-use asset	(209,587)
Accounts payable and accrued liabilities	95,090	(9,677)
Advances from customers	420,406
Income tax and other taxes payable	(1)
Lease liability	209,798
Net cash used from operating activities	(276,014)	(157,474)
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party lending	677,945	157,474
Net cash used in financing activities	677,945	157,474
Effect of exchange rate changes on cash	12,832
NET INCREASE IN CASH AND CASH EQUIVALENTS	414,763
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	37,555
CASH AND CASH EQUIVALENTS AT END OF PERIOD	452,318
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income tax
Non-cash activities
Shares issued for repayment of debt		10,000
Related party forgiveness of debt		$ 52,087

XML 30 R49.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	9 Months Ended
Income Taxes (Details)	Sep. 30, 2019
CHINA [Member]
Income Taxes (Textual)
Income tax rate	25.00%
HONG KONG [Member]
Income Taxes (Textual)
Income tax rate	16.50%

XML 31 R45.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accrued payroll	$ 35,633	$ 7,589
Other Payables	76,085	9,039
Total accounts payable and accrued expenses	$ 111,718	$ 16,628

XML 32 R41.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details 1) - USD ($)	Sep. 30, 2019	Sep. 01, 2019
Notes To Financial Statements Abstract
Operating lease liability - current portion	$ 66,473
Operating lease liability	143,325
Total	$ 209,798	$ 215,298

XML 33 R20.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Schedule of details of the consolidating subsidiaries

Name of Company	Place of incorporation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	The PRC		100	%

Kangzi	The PRC		60	%

Schedule of lease terms and discount rate

	September 1, 2019
Weighted Average Remaining Lease Term(Year)		3
Weighted Average Discount Rate		4.75	%

Schedule of future minimum lease payments under operating leases

	Operating Leases
Fiscal 2019		25,409
Fiscal 2020		77,074
Fiscal 2021		79,615
Fiscal 2022		54,206
Total Lease payments		236,304
Less Imputed interest		21,005
Present value of lease liabilities	$	215,298

Schedule of foreign currency transactions

	As of
	September 30, 2019		December 31, 2018
RMB: US$ exchange rate		7.1360		6.8764

	Nine months ended September 30,
	2019		2018
RMB: US$ exchange rate		6.8618		6.6146

Schedule of earnings (loss) per share

	For the Quarter Ended September 30,
	2019			2018
Statement of Operations Summary Information:
Net loss	$	(395,913	)	$	(147,797	)
Weighted-average common shares outstanding - basic and diluted		1,660,239,731			636,661,604
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 34 R24.htm IDEA: XBRL DOCUMENT

Inventory (Tables)

9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Schedule of inventory

	As of September 30, 2019		As of December 31, 2018

Raw materials		301,725		-
Finished goods		9,409		-
	$	311,134	$	-

ZIP 35 0001213900-19-023387-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-19-023387-xbrl.zip M4$L#!!0 ( (-C;D_]3:R.LW( 'KT! 1 :'EB="TR,#$Y,#DS,"YX M;6SLO6MSVT;2,/K]5)W_,*^>Y(E=1=$$KY*SR5NT),?:V))6DI/-^9*"@*&( M#0AP<9',_/K3W3.#&P$2O),2MFH=D01F>GIZ^C9]^CKW?'_;NSR\LC]G]__G__'P;_^\?_.3YF'RUNF^_9N6L< M7SH#]T=VI8_X>_8+=[BG!Z[W(_M-MT/\QOWWA]O/\%&,_YYUZMH#.SXN,=AO MW#%=[^OM9338, C&[]^]>WY^KCOND_[L>G_Y=<,M-]R=&WH&C\>:/ 3?-\^; M#>VT<=IJU+\- .AS/8"?\#OX2=/PG_:]UGVOM=ZW.O]?R7D"/0C]:)[&MY-& MH]EH-$[%Z__X]N#9UGO\EP'B'?_]-]_ZZ2BQM.=6W?4>W\$[VKM_?_E\9PSY M2#^V'#_0'8,?J;=LR_DK[SWM]/3T'?VJ'IUZ$B=7<[3>X<\/NA^/C #.>'X* M$OC5#*(7D@]WWHD?4X]:N8]VQ:.6>M3DF>=\;M0?W:=W\,,[W*'CAG;UWJSUB2?4"Z%__*CKX^B%@>X_T,/RAQQ@X!?/M;F? M^P[]DO.2XSI..,J'RPR\=\%DS-_!0\?P%/>,WJ4.X$53*)OH^\M$W\96-QC!!E/[:1" MT]GEKT<_ P?1&B

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�+]RK:G\W,[;&R!QL\ MJP7,(BPU(9KEC6*?8F46M,)6$*=Y*&R?GB:%:0Y\I81)[LX;" M6C$%B^FVNMVNUFVT]W MI1+'"S=).VV>G+;:W74O3*7=JY2^I8['K*S"XT;* MN3EGOE7 FRIA-"?7<2M %5<[V@NTC2UDW*29ATH**K,A06?,G>$ MB6O!OOF?T ^HFM,*2I#6.9WRP:T&RJ97MY2L6C^*5Y%7ZX9F:3IO=AI9#^=Z M-S]5O&RSLFE&4=-E#N5JD"]%I*LB:Q627&WN90FPV6@GT\E7WK0;SQU8P6IE MDD\[IUHB2R<>LN1D2V@6"\^QBCQ?>++E-[>C)>V?XHD3; ;F.H.Y+2>$;;X> MB!Y=6]R&?"1OVY^DJ&##<*X*W0L0:DO$ NK MG*47B(YUG?8MH@:> M_+9VVCEIY\RM!EYLYOG[7KCMRTVXP)87[OAR,R^YV\W&27LQ*- R_(4[\)C= M=\R^.<* NP!?>EJ5V;:U9K/1RUBA<^9:&;XE:&0;8*W!K;#(=$N33S-U$;,, M:NXXB?05::?7ZB6V*#WF C,N)9%GKF"5;9PQ\)(;UCE->NUGH^D7#UB],-66 MW95FI]5+U)!(C%AVLJ4VI!CR57:C:-0EMZ+5:VJE4'/F^L'U .OP..'2YZ.E MG:9ON!-CEI]PR=O!8OA7N^LK&G?9'>EVNR51)+]>6M'I]%I:@E^IX4I-L]0F M% "\"OYSAUP2];W620ETE*IWVLN$#Y[EEFP]6[Y12'&9OVZ[V6PGLQ'GE4PM M68-V1PO**1B\GA5MO(_1 A5NU[5'J_<[6RO04W7<5KY"G9^2<=P$F=9*L-#U M0+&5M4T5_$VOK-/6DB[@@UG8["+#&1]$Z_2D><"++.7=Z#8;*0K:/NE:Y39XI@KQXK6!DC@J*]P.;_OS6>8\[M<"P=$Z8,%QLH*GOM2> M%C67FNJ.5=3H*BJRM<&;XF.M@Y=;G9.RK;&FH4_5$5OLW35$EJPZZPQTKY,R M-@CF>L6W( A59'@QB+>PV)UZ1W:XB2N(Z+W>SZV+W1VNI9R<74FV[(=0 =6@ MK;7:947*4K)DRT)DWZ7'KL4&;7D9)K,,=WEQ8F*?Y,/QGFW='DJ$?1,%^1#? M#WE>#]L=R@$MVQV\+,PE%THM*G/7N4A272GX4E.M#-Y.Q<9J\*W;65B./+:& M_CT4')O=KQ4$Q^GI?NW=GDB.S2YB#9+CG#\$'R8W **HGBK<:\ORSTZS@<%T M,T9>=/)M$;YZTFE%+I+6"M+7EKEF29&\OHY:N+Q@_FY%C.SL NY9<^[CPW0NK MO5C]#D.*VZW>R M).0-F5^.EHV4W>^152O='_8=TS\#P8//NDV MT*POU$_ E,=UGY]S\=_E*Q"V>]U$FN,BNK\"98&9<5R]3CBC><^628W/TR^^ASP^]%R0+D )MC'CL3$[I9=?[?72R6D ME)]Q;;"6YUN=7KO77@>L$K!N4DUFV_Y6)^@3/*Q(%K,BG/8^])8+3O?FN!< M&J/+PEFP$]C-U ^6I=,E#\?\23=P(J/2LJN?R.-FK]O0YI-YSI1K W:!VL[E MSF0)8+-BX](!A1,VP4QI"A.,GE^^X'FJ<'O9Z=8'Z6IJ3Z4Q-?U-@=&""#']E(!RO:><_PT<:/#(<_ MUFWK$;Y"!X0UF!S][V/P(XZ.@RXZ0?3R _Y!R_S?_]%:/[H#=@/F(9P]U+/ODH'.JL;\-[@&EK ' :BUTM$8 0"#3%L,,[]4,FF!=']B96P3=+4%>: M>)A.W^#N#UR/?@F&'N?TC6,YG(T H*'/.,Q@PM1P%M#%REJ-&D,O+CY(, M#H/S!%)$#TT\#G5V*4Z'.[8<(!B<"-:A/Q(D-0;GB^F1R]AG;RR54U":?>PMCZD&"1D>Z*=" LSL@ZWQ?]X"\73;0+0_.\%AP[*(%@>A_C'28VI*\['H>>'*.V -HE40Q34XM7'4%Y5*3J^0PXCS%!\ M0GE[D=!&EN^CFH6P&5#9!G$4,1W-0- M$$1FPAFP73_$"$+!UNA Q<29RZ75:B0I3RDH7^MW=89J10(#[L@*@@P"_- 8 MYF. #J1?H&'X0S>T33S:8%)$0(!P^4_HD,(@H"C44' N%TV/%%ZR1S(^S7W' M"6&$6SYVO8#!H_%I!5XPL&R)B6A6V(KH'">X3/%Q?A%'8LNK6!W@?F0Y%@$C1,D%I);98$$Q*#:Z-8?/^*]C$0KD9NVV/=1,:#+@3Z[(]U0WV6 M@#P GR EW[;UL<_?,_77CW!FS6"(0#:^_Y$M!G $BJ?F>0+&!TJ!K9#SX :! M.XJ?1E\!O6$F473\S*W'88"/VZ8 XIA^?L\PFL0R?F1R 6*\]^R#K1M_,:W> M 4")-&B**WU$NHBR@1!S@:F0N/"<$J_1I#1=WE;).59:8)*D#%2ZO)*+OH%O M<=7DF_#8._P.F:KK =N,?1*[PP.0&E"D\]-1\VA;.$E6W4GAA5.1G@RJ9!6> M[POQE(L "?*\5X\.;9J-=:[9.:LU. MY^VLTR8/>[?W?1J[-A^('?UTP^ZY,71@Z,<)^PQV/KHPBA"C>,?W"Y\*^6:S M\7W>-M-P'U % X/G-PMY+[OTP4HP_YT-> M,'^6,-=!-+\/86/S*&7.@A?%;<'>;FB&1;8L?Y\6?''^A-L^X?FGFD]"]HGK M=C T4&,J<<37M-&?7-#8?H5_]FR?9YW'ZA!6AW"Y0XA?_?/NXO.F=@R]93>W M9WNV7=59JL[29L[2K[KS^+?UNDY3=TV'B?XD P@^Q5$%Y2[HL]?Z7WU^/;CP M VM$]YB'?GT/RU$NJ&A1A+#JYGXO5J&\_,+AK:L+N8*+<21']">#92\\T.0" M]]#61_]Z?+N(ON^1_A=G/*)D]$GKOA^.QN(&@&X1=0KS)@C0_:B/*' &1D1' M=.RIGG^M2J,;\FI=7&$&> 7_)0;I@=L6?^)R9APV!B[T8U^_0 6.4>Q?]\@S M[[L.N09Q\K$7FO#;CVSH/F/AR!J $X1TB2JNZ@QRZ9L6K-B+;M3\!!!U=A?' M"A P,7S)F 0=';!T%8$>>-,-'X)!:*L "=A="Y!@>;1F0#CW_>CF^=%US6?+ MMFOL2;?#:+=-#C#AW4V@?Z-7<'F$^,0:*[ZY/ZM0?%-%+2"'LK X M.855#$''L"= ];!Y<.8QAUBZ!E#'>-%B(GJ '& UZ 3&0\@;F,P MA$'&&\ YM^$<<$BAIIBE5'$""L(9$F%#8@@ M!H*!&$$.$$P?CSWW&YU?G,[R*!2$F X785'IH(\?9,0%<6;+9T-N$Z@/NO-7 MQ-@4[*!(TLRQPX,8MT]A$S!O(&(A'B;L(S.'WJTDK/89\_> M''T\OSP[>HM;)'^&!>*FBBM4WQI9MNXE?A: T+0 3 T?CX"9S]Y*,;#I*%,1 M=+SG\9W' QV0-7F_"*M+Q%/O-8=;9&W[S.,66$=R:U2$%ZE!H&P)%0I4$3@B M<)H-UP_P( !@?_% '?7[9>&Q;I'YQ)NYR# $[@=G[97I$Q]EY%XR MF":.THC%I(Q]AD=(*'H3/'MQ%"0*3RDCQ>%+"?JY9E1TR.-X1)!U7^^^$X,- M9/01SBYI*!N]"?/#XR*0,BCUR@_IJ&DES&^_?"@;L(T !_+L$L3 0 (863! M.,BK$*'''(#B*L3,$U8I*57"YB&@$Y9*%,VIF%3NNQY8>TXH#5R,Q 3]"=0P M69\CUEXR4 K^"4K1T/*1P^*N9\9_'G(G,HT-.5XJ:MPU"*FFP)2P-,EPC3E9 M*L17V*T8RH80P&>&U.$Z:*+!KOAQB4#_!W6#GPWF%$J1D:Q.04$0(V#WOX!) M*-'HHN4IMF @>$], .G(=X^G(M- @QM8)$IP#%J9)W0MD#08&\L>EYC%#".+ M_K^A#JJP-S\<^#4%H1YXC%-*UF66'DNXTA$G1PN-5Q2%TXT0MG1X301#WY>! M1YM?SA(W#P>S)6N-<4"=;K?E_, MZD%+>4\Z2TH%*$3$?D=@]>I::\;=VOI V-/U=^LGO6Y[_>O/$FY\Z;B)N/,T M%)L,;Z_TD\O8RP;W977RO=K4=0IG"4.S>7+R8Z7' MS$15I;'D:RP)"CI_M*M9>NUNYN7GLYE-##/0P,?'$+FJ?9'J!2N]*5 MS:$Z'554!#K=Y87\P./ATP/@Z'K67^3#QE6$X0BRYK N4(O_3A1.PB!P[(5<2@871/( M8 D1J14E=M/]OB$3LFMJ)Z8NTZ+H MQS'W?-=QN!W_A+%(_!LW0GRC)N\'N2SD@HH]WCSZX9@*&T3O4VD<75;4KZER M4Z7A&' Y\X,NH[N(O&IT=\6I; 7,:O-'O/]S4K6K?.X]60:B(0HG OXR&%@8 M7C4&CE8C*##PB>*WX.T1QV@Q0#).6TO4=G"!#PVY;AZKFAP$Q7QFLQR/**PP MOM^\9/%0";$PV@:J-;K77..5A4EDPRZCVW4\C>(6&H.8N9^JPM*_.V/W[M@R M6*_=J#&QP8PVMZX^B;=$[(,HKLNHE(R(#4B%!LB2;QCCJ!M#FCJ.2TB<=5'Q M!3D/?L**58FIZJR/->#T;VR,]?D?)NEJ&XG[:HH%L?SHXK[.A)H@P^9A!/CQ M@<))71$AF;Y"%]?C5#('ZW+I<55B$1H@ZD8QL*Q&*BJ?[MF=8Q$]3IY8C#2W M?!%ZCI]C?$=0 ,;'KB^BX2T,Z+0-TA0$A]7AK"0S87M A?3=.21#%L@SWT;%F1+MG(S\$XX&,8^EGW3+^>/AB1 M0*0222D,A90BJ"+ RHSCDPG"0U?=D9L1K"A[9TU5,"0O3 MI5*B*:H_UAK'C4Y2*-3D)DLYX+/'T#*C?!O)3/Z.M3/=%[PZVGK!U65Y0VF" M7@844V=XU@,>2PKO]S'4BF+N!6\2O#?UMK!W1\CO!BHH743/21X056[*GUVP M"() 1XG >0Q*I"'@6"AT?(3$BW"A$O% 6-4@%ELP^&DY*6H!EM<>@UC5R1' M\(M +51<#X+67N2)P7A34NYQOS,;C$+ MN.:/I0#!P+;)OF98,BADZ(\I0'% M^Q[S5UGH.7"3)4-'.8&*B6&D<58F1CS?7LEM 26#("\H!/*E&3@R-)5P?1=X MH8'BKK)R]F<56<$UU$W6K#4:#?5_$:DK=,C8\6E0-TB8$8BT!F:%3+ABWS7J MC8:&W@_Q7DVDG6FU1JM9:W>[R1$M:E06515VPP#U<5*UB@OSXMG7:EI;J[5[ MS=I)5YL>C4V/5+KH:Z:7VJRS.=5&2NIP-UST/W]I1UFMCS;K#2JX;^-]KH[T M_JP"BT$8D4TBY5=VPT0>57R(P?"-J^NA+$W^*(]!QM1^F(#:!7H;IF'OS'TRE#WAU+S4-FW21OI\B?*ST6 M:.9YI.!/Y'0R14V5\1X%9UI=''5I'"WJQB5J%F4I^FE"5*#/203XJDJ'$QG]WY M_LZ-NJBB??<[VO>CE'?_DJES%].I<]M9;$ZLT(O9L#6'IU;!NX<9O%M$KW?* M1XLR_SK.^+X+1R.\U[N,.SV\GUI2#JQS\5W\SIPA=S+COL1(8[#CK$+NV-@< M5;1"JDL$V*ZG+'YBP'G'I""F][MYP)XN/'8<3/JF==JIG6JMI1%2 /3;"L,* MPUJ[5^N=]C:-X8U&>!<%%L_:P]^S/@1E)4M70L)?<$RW\H:\MQ(V^1)R80&B M69)22L1>+TLG6JW;;0#S.ZWU6MIBJU\>V)>*S&ZK"^@$E#:*,T'7@LI=E[TO M(^R2=P\')N+Y[G&J)ZZ>$IR5.$GEYCI14''G5JJIJ5;5. MG%2MJF:;+U6KJFVGVE:MJJK.'CO1V<6IKEI5+7 >JT-8'<*J555UEJJSM.NS M5+6J6OTPS2JP4>QK^,>[%1T>!7Z3&=4/*H?)X04R5'5O]VY+JKJW5=W;?8F0 MJ.K>OMC*<;NI>SM3[I>O^%6I#"]#9:A*T^[)IE:E:7>"JDJIJ$K3OE0%HRI- MN^>.P!>WH UYSDJ[O*;*4T1#9&.4*,6X[YCG(JRN\IR];C6XRMDZ/+VMTFH/ M4ZLMHME>5LU7E;+U$#%5L53E;+S,!J4+9RK)J65?, MBJZ45!#3+RZ\=^9B15OGX,L*7EW?7Q JFTR0WDE3TWYDOUQ?7OW"SJZOSBYN MKPB1!UIE*7.>#G05YU1NFJ LT\Z>"D6Q9"E1*KH?.JITG.A^$F!=,7_(!K;[ M[#,_Q)8D%A?]$U3_%"HW'5FQ!(')_3%H?VC?BKC,'WSV@-7SN)]XED1'-'5< M;AU^496"Q[ *+-']I%-1_;C8F>AU0$?*KV36J?5H:>?78_Z MLQB)4KK)Q[LGW5JG=UI8,[7.[JD4]D W M?SF:=;\,ETPX> Z0^@Y"97 2B5 MC2=$I3^LQ1UR41;YT56T8 @F1"-3S6YZETHRYC4D,%UJSZ5:VHCZZ$BCXN=, M17TLX8SZN 0#&V*ERD$3!*JCP3'5V*="K[*CEG1%JH^(P>ERTLG^"U0*?:1C M&P(_M.&<#*EP77)K'WB"AA52"(X8,4PAY9#/^\O@6O=8K4X0*ARS!ZI9!Q0@ M6B")_4XPG0$HNK[J06$FNZ$X )QHB2*(RN/Z -G?LV7;.*SB9K)>(E**[.>0 MX5STNJZF4J_K3[IEBPXG^#I,)EM(N:&'?,D/L5BI+ZJ$8N\IRAU51PQ4"/Q2 MM&>**O*IE^OLH$XT)IQ8 M&$Z6?L2N=T',G.OL8^CARR/7DTVGQ%"%VX.HI.5'VT*H$^7;%=IJ.9A$_A\$ M'C6>@;%@2LD11%^7";U"$"!'HKXP.O.!_(@] #5$]0SCI:39(_]F^4%4]E76 M/ZVS+[JC/PK_*W4C?&8^Y[*O5J(OB)'8#JJ,+9M\N-AZZY%ZW^@&+9GZAE'K M!!<+U'-!*$1>:;E#2/"PATU&Q%%_%T5$%C4;S)5KB-@RQ9,3>B42RLFL9 M4TG=7'7@$0P6P8A)D!8@"^XCLQ4M@G31CO&)2[9/P@/KU2*V)"^-NI0-W6<. M%%6+FR:F5JL;0PM^%TK"PW\X[39M]*.KVS/:DA7KT=F[SS-04$ KQ_]@]>\G MW4:@SZ,V$]M3P->H:[=2NO99_^X3ZU^=BS\N_O7U\K?^YXNK^[NM\/Y*6(E5 M((4)\D=-!=5B'M,;$I MME(28_GR%VE3))V\09>C,D16> #49?0"3IPI:%\X+O-S.O)061RSMQY4KBV^ M8G_NAE_W;32]]T%W_@(BHT9)_O'9$&P,J2NT3GYDGWZ=?S>XEU&<[4ZSUGK- M8:RM7JW3Z:Q__5NYR\TRK/9,MKS"JPM<<\! Y#NS^7IN.8K&*T_#.4M=WW7K M >-M#NFO 6US"ON5-B&+XV[SAZC";2N%NU*X*X6[4K@KA7O/],U*X:X4[D-7 M'"N%>]\5[O5'9951M%/!6-=X@WD+2@(\"P\=^,50.W4Q='W_Z>*6W5Z<75S^ MUO_P^8)05]T'K1U@HB&"QXL(2=WX^#NZ\GF%VU *S .WB5^VL99O^":--5;9 MO.NP>5EE[U;V;NG*"A_#_UBZP^Z&NO/WT**PHP\65OW&^9,UP,_<>HU]#LSZ M\GB;!I",PQFRH)DQ(X\T Z@&(8ZT)5#$%3J[6:;;8);&W%FD[Z M@(K9/RF!NTGWG4[5*I;PW9VY9.._9K ME=SUV,,RQS]3=H,S \XY4?-W]I6BC<30)M$VSZV5^6<_C.87$7Q[+;*)KHW MQ92I$U$F.1U?3W84-[%/E\MTYKC.\8,EJ@+8/,!\$#"=L(D7P$ A_4NHO0C$ M&YSTJ"^B_[VCMS68#.^%,'?KP7*#^+VQYYJA@4E+3HA972)C)=%PK8:9&QY_ MF-!"U)!,?_2XR+.2.08T;T?[7OF:DA4/5&:(F\HC87Y(\?:4" 6\6K><1"Z7 MR"#P*?!?+">)A'Z<%W#T5JRY'[FY3%UD]@5#"Y-Q, XY)9(-DJM"\S,@Y*0GSO<$J M+UCE!:N\8/N+\;F\^7%;97AOR& %0FIBAJ^(J17%]95 M>8KVU\61]&6(^:O,H?7YCZ:05J4254ZE'522O_'X6)_0ME,.N\JA*Y0/- M.495&E6!#SD&.?JK?)'KM69526-ZEF%<<"^=]TIL>>O5W71E<5061V5Q5!9' M97%4^F]E<5061V5Q5!9'97&L=M4WU^@H+K1VZ3R!V'*]B>B2'%2!M*_76$G' M>I8P5*JPVD61J@P45H765C;)>@JJW2YF8:PS?FT=T6DT1JNAU7K-#50/.Q0$ M+!5\MP?J]R)6\D?+L7S0.]BCZYK%E/I2&Y^>UMJ-A87ENI3TEX+$XG.R-R;K M 46F[HD9UM*TFM8JWPZX,E^+S=?XK_)'9:\*$LXV2*<,V40OL@MJ$W?E!H=> ME%#34H&LV*#J_@_"VH%FF[^,G/G[H<@;5XG9V*_3,V5*=A36JKH5!I[N^-B. M#W/"D[T5+8>S$NIL6W1D[:M$_KAJ0.8142U /7;T5DSZQ:NS#YA; M"4\\LK[S*""[\;AO8=/?&A90X -V\8T;HJOC-;;]Q,:"V&WM;*A;WDAW4O!F M"A[4V4WH^:$.NR=CNO''66M(ERW >1#,/G:"C.HO&/0F;,)IK='HUDZZFFC( M2)X2>!4.!B.>SL8>?[+!QS 22&K:*KG=[Y*M([7::JE% H;E3$3*P0Y>LYD5IQ#M]^T7T8"P 82TT% M*8;Z2@N6I;0/0[;2!H)KPO\[6JT7$5P-Z0C[3#O4IOKTI'X:EX62=(AS)BM$ M%6@LU$H<)Y5P$1#$VQS0@&!AC[)_M%@JX,B@$*'O6JT.'@& 5M"U']H1WRS" M3T;9,@PT(DS)#[&O=ZP]PD@)J&IX>M*=O*'CZ(%.VBZT0]WW/!XH'N3 MK&8I]#4E)K#K-16XBF!CSP#((TSB8/4I$!<.-\3WD0@!&Q[QG8\*G Z'P'[F MO-D">U5KD#@E!2O;UA&4(SMI'O1L?X6KU&?<^LA1$J097 MA$0$2&(7A3)^2-&B$B-I>H1'A98=TD08BT,JO(8*_3.:!DD%'O@_AU>PLN)B M8E55("0@%'F;DFH;6)RAUNT2T8)L;S5K[6XWH5 F+!+0'=F3;H>/5 M:-*4F@@@EG"29:PETK9H^AK )-0B(^FKDQC+'5FYYA$;CQ44V"O M0;N!-0-; =7'E]K*E.=&G/?IR5TTU,64.<,+,14^^/R_(2 &!*8!FVMS5&A< M5/C1"=%L*&]L4N^?XU\UR7S,NG,?A-;ZP(-GK'$:9!Q:"1]FQ1]VOHJO#H@B M*8NPMLVSA6H.R Z48J90NPU!O^)TBVJV/FTC*/&9;V7)VT%DTO@H,$5577S# MC"X1@51UL(6H#*ZT%:5&!>8+>3A)#*H3F./((L]4,-2GW5-(UFF?EG#1BV,Z M0Z#2< 1$WI YP9MJ_.**O M?JF9O8U$_&/%[_=NA7\ V4Q>PEU=GUU\NV'W_ MWQ=5 :%=7C!8?K(,]]?Z79U]Y$"E<'@#_1NS]6=?R)UD[6ST#R3-9'0W()G2 M*P_N>OKG13IJDU_@TTIP'2&M(?2 2=_O"4TM>M=[ZO@PH+-".A MF(1L-BA#W02JPV$HN4*2=^**3925QT] ?98+LA)(7IV-L6Z9^= A.98&8?6# ME@ B<;A2#&#A Q8-61VLG:\BR\VCU@*@&6!;!TN>F[$-!I+86G3*AUS^3:T? MD';H+C&'D][!<@00$!ZW^1.9#E)P2'?J M8RA,!RE(HO.=I&7YF8GFY7#,FWAD\^0.G2T$*W6JA+GG6]1X(5C\^,[7X&8I M8H5*VP6<*IK?V@G_VH>L1!$%7W^>G=^Q+[YUGO'LG\Z"KR0'[%W MRPQ\KO6$(M@C17 #,WSTW!$:>\>-WG%#"USQ]^EQ^=E,;KV_ $H,)BG_%PGL M,[0EO,F9:_*9"N[5;_]X5W*<["(_@]'#^6?T>ODW>/\PV9Y.G7$< M=$V-:!_P#[%*HNB'B+8/E-V]3*:MFRY=-/:!KX;BSO0.';A@G?KLZYBZV5RY M=;0TN\>-9BW&@MA;]N;>'5L&.VDWW\:_O>G??56OO*4;2GDE4A/WN5A/%"UI M4U48!:YHTS6''L/Q&%J"T8<.>@?5/ UA4#\";_#P?@[8*=T'^\RFDT6B)M); M$HH)OB6] ]3R"*>S+?W! NO;DH#@,W"68;2Q*[S8%)Y][ Z.47]YH\@@II5KN^$/. V'KNZ)_$/ 0[@SQQ[3W ?ZE# ,E#X0'H\8"4+Z1;=(Y+/'!="R_,\](&3PV,[VI'XM][L6,X,:DT? MFYV!<5C']%I1+0%JBZ.&NCIH$W9H"O,DH7,3,:=)]0AH]2@B5B0H?PAJQS'V MGJ*/-JC1XE/^6< 90H\"OS"%AXRB%+B4"".3AG880C@' & C/*Q[3L8AU M('\?,T1&0')B<;;=J)]\ L;X(58"LMWQZ(PX;?82:1*O7/@ 10KN)F@RBM3) M7&82'2,7#2DJ0O!_>T),#M\DHS,6&3%!9\FX: ;A#$/+ ML-EHOCJ[SIP[6%;RF"4!P .1M*&#R+Z- EE(Q#[0':B4* IF<;D)K#\#E_O$ ML^NG6*.1ZT=Q1O) FJZP6Z0X0AM^-,:8EX"L'F&Y/'.F/%] M;#9WD3$'>!T MNHW)\9X(_?6F8+4'!J32XZWRG))U=*4!2LMLY^ M3X"7!!Y[ SJ 7=VT0 M00^/\PGC+LL=HFYAN^Z[B4SY%#=$3!$:$Y9%NBI@< M_DT^*(9!,\]!UX0T*>--P'*W^+< K>*1:U?@OL7^T#%@3A5/I MOHM+F! LZCZ2;AJ>T>*U;1B,>X9%"(%OQ2QU1MH8N5' ;J(#DB$:&CTB1-PM M.,*>3B+#QAP6V%8K2UM".4/Z.F2V\S*89]\4>ZV"-W"3?*FJRV Y(73%L03^ M T=7;KFZK_VNJ75JS=,3_#O#M9(_33-2=UKBBKNJE/*;:%[I4CPAPR(PBLZ1 M(UBBO6;R1HMILSM+'L3FY*9N'O!ZP'XC$*4-%]M8Q'3&(9E5O(3J4,J7E5EZ[,]:L%Y#V?'2H.35-EJZD%$$0UY8 M02VN K7Q-=H[J[]S[AU/]Y@^N>V\+,;+? M-6E:\^'>JYHTN=MSKCCJ+7#4J04MBO9E<9V/X':]5USR*'>J[^?@,UN&X7"D MPXO0@I2SG(*NOUDC$N)A #H$0R-V%(ZRBHMP561G /JB1A[(I*7+5M:&6[%]8?@?F#33&S2N5^R^!F9V;5L/T5Q!'JF],% M=7\H-7=PZQ2D&CF)\>Y#G,+3I8?!1O\CV^R9B#LN@YX J/ M\HYED:4N2P0(8+1,$<]"-&<&@I@[3O7P]4 F%#._KYIO5'XTOC/ 9YT=$7 M@D[%,F HPPWWT *;!5VLD6[[/QU=7GT\^KE1;[1[G9*@YTR= MGZ>8'N6S/#<3M5OG(;\"<.^?N?W$O[A4!;]H"=,9FO$*&D<_-SM@HF0=%8M/ MO^PR,++G_ME=%OI>#ZR!Q:&7LZX$]-#C?&FP3T'C7A)LG'<5P#_*B.)EX.ZT M0<-<#FZ<=EFPEZ;M5A>TK<7AS<)YRPUN/2$__-T*AE+!N93ZS14/^I1)N#24 M&J@+,9#E)E,@4@O3F>M:'JP.""_9)'7F#+.Y[RURP.O!5Y_W*0LD"<[%,@GQ MY8=?9+6-T\Y)KXB-9R99#T0IV5*,_RU"U&K\Z7O!G]>8!W@CTLI N1DVKGYK&::]XUTH>F?E0K$0[A5#<4!S#W]*;@.-9.VDVMI9TFV=N\.5:$:H'- O!ZO9-.J[,*>%&GK:MU M,+?"T1985DO3M%8[6<8D'C,[GRQ X(/T0Y'3=TSX!D S/\>VFFPA!K]=N8[* M'EZ,$+1NMYF@QV5GW0CT"V 6$-O3-K".@O-Y5A;72S*YO/$7P$:WV^ZUYC*9 MLX66O B%+;GJ-9!!N]5J%MI\.1/-H=M;DU-79]E!&P+_">_*7>A.?TA,])JL(V :EG9MXEKZ<[_,M" MJBI(G<"I-HW3\B[.Y7"ZJ+=[B9.PS!XL/>1.9MQ1-$>O6Q3>D*WG84=,^3BJ M44,5^USG0.,_WG2[-5"1E@X .=24Q^*>R?L9\K+,76 MRXUG,X^;G*QH*NBJ>-5G=YP+Y8#G7J53=WJV_XS!$7\7JW&\UVPF^7'7Z95XZ9Z+'YJ)7"CVM?=KH-!)@ MY8^[S/2+X&91.(0 H>9=]^X'?A9U+%UP_8U3(&PECZ:'6VBZV>N=QYE$NS,Z M6+]1Q-^"*]':6NHF(3O>0O,MQ.1;S7:W6W[BA!!8]-2?=K54R$\\4ME)%CNO MIZU.:]'IUJF>S!]VA0N7W,%G0%#Z(JWLGA5<:LV9/ M.7%I[B#,BTM;;)/)UEY\QK7!NC2"8I='%'>/EG RI'TWC72.(J_-RRNOII;V MD..N>HB]58NYR\N.5Y5"K4JA5J507VN"MC+N93L:_75S= M7]_^06BJVABO'>"(;$0_#M?Q+3_P59,54= =&.1VJKMN'?\O06=Y'>%Q5(N U1!5^!,// M!RV;/;JN6;Y(QDN)A3N=62]M+=%M+Q^)57C@"PQW:VE:36L55XY:0]#;B\3; MNB)IUQI$N,?VZ78]!1MJ('/E$H36:*Q;'G4^?-9]U8W5C-KA6=++0!UCR0Z) MNR.B&3>K/6).=G6.BVMV1JJ/CC3?=[U=.,NE/&;7-Q>W_?O+JU_8 MYXO^W06[O?SET_WQ]V<5KKG/261LP:_)*O#>6+V:SKWH"=U')_G>Z=>6>KO0#_ZV@SLJ M\ZXR[RKSKBHF5=EY!VWGY1IT53&IEU),:IWU<5Y.H$A5?JHJ/[46]%71(B_0 M+*Z*2;TR-\):7 CKG7<5N[I_]Y7 W.@>]QH,H__-[0\CAX"'?0XV$K+D%?0 M&+Q!3GOFQYR!U\D&"@ M-ZW1V*9. Q;]0-$9GF[0O;7C!@"@;EKVA)D<+*21Y> .U]GO//HB"2"-Z#KP MS7]#W8/?X<4'W8>AT#D2CDW\'6=YEKEG!()RM?R$MP"<_)]]\?LWVF6+ZO2?+=H?^7NS^M(\]V1 M3K(F.;"],+L-K>5>ZACZ>.RYWZP1B6EJTLE&HDMG5C4!>N8><]/6/X:O;OZZ MI)+KE5POE.NQ/TJ$-K]L:1ZUF9^AMNRWC&YV9J9:[:^@CE#?;.R95.[U:HW> M/O5V+T/@:91J^X;2TUI76U#5V:]PIF1JI\)RMS1Z#OC"HZEU:LVUW _-I8.4 M=Z&H9^:L5,CIKO'PPIGK!_?.)(\F(^ZXQ]+BSIE>A::J)NT-9=[+L^&S-#?PVQ.)$S*-?@,;%G> M<3K*C& N$;ZG[I>R=293_H>5T/7RT%J8GZ60>;)&9"XA2K9]"-8]]FY@6)/, M_I^SLXN+CQ_+1/%)+\I*M%HR@VL^!:[57S/OW"X[]DF)L0L#Z%9!/4M^&Y!=,\%:0^.:[4=&]Z. MLF=TH1.9O:NU=Q,X MO\[=V(A]M&:)7!G)&S:24\EJ+^U(OL8-K;P>E==CQ^9YZ;:"^RU[L@KWZ1H, MC.4SD5ZS4;*B17B8)D:)I*C=73)L8).CO*HM:"'?L\*92DB_E#PJ$=B4Z".? M'STU'63E^SS36#CJ*OU%#T(/_KM@ %:5NE.E[JR'Y56I.U7J3I6Z\UBE[E2I M.V5WJ4K=J5)W]N>L5:D[5>I.E;JS[ZD[T]9GTHY*< 4=<# M(8;1'Y4R-?O^]0#5^>/&Z3&8FBQT+/'#U[OS(V9RPQKIMH^VY<_-#FC.)=

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end XML 36 R28.htm IDEA: XBRL DOCUMENT v3.19.3

The Company and Significant Accounting Policies (Details)
9 Months Ended

Sep. 30, 2019

HP Technology Limited [Member]

Name of Company HP Technology Limited

Place of incorporation British Virgin Islands

Attributable equity interest % 100.00%

Heyu Healthcare Technology Limited [Member]

Name of Company Heyu Healthcare Technology Limited

Place of incorporation Hong Kong

Attributable equity interest % 100.00%

JSEL [Member]

Name of Company JSEL

Place of incorporation The PRC

Attributable equity interest % 100.00%

Kangzi [Member]

Name of Company Kangzi

Place of incorporation The PRC

Attributable equity interest % 60.00%

XML 37 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Inventory (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Inventory Disclosure [Abstract]

Raw materials $ 301,725

Finished goods 9,409

Inventory, net $ 311,134

X

- Definition
Finished goods.
+ References
No definition available.
+ Details

Name: hybt_FinishedGood

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Cash and Cash Equivalents (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Sep. 30, 2018

Dec. 31, 2017

Cash and cash equivalents $ 452,318 $ 37,555

Bank Deposits-China & HK [Member]

Cash and cash equivalents $ 452,318 $ 37,555

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: srt_StatementGeographicalAxis=hybt_BankDepositsChinaAndHKMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R31.htm IDEA: XBRL DOCUMENT v3.19.3

The Company and Significant Accounting Policies (Details 3)

Sep. 30, 2019

Dec. 31, 2018

Sep. 30, 2018

US$ exchange rate 6.6146

RMB [Member]

US$ exchange rate 7.1360 6.8764

US$ exchange rate 6.8618

X

- Definition
Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.
+ References
No definition available.
+ Details

Name: hybt_ForeignCurrencyExchangeRatesTranslation1

Namespace Prefix: hybt_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition
Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521
+ Details

Name: us-gaap_ForeignCurrencyExchangeRateTranslation1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_CurrencyAxis=currency_CNY

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Inventory
9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

INVENTORY
NOTE 6 – INVENTORY

Inventory consists of the following:

As of
September 30,
2019 As of
December 31,
2018

Raw materials 301,725 -

Finished goods 9,409 -

$ 311,134 $ -



No impairment was provided for the inventories as of September 30, 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions
9 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
NOTE 10 – RELATED PARTY TRANSACTIONS

As of September 30, 2019, and December 31, 2018, the Company owed related parties $957,409 and $279,464, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by a related party. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls.

A director of the Company provides the property for the use by the Company without charge.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R47.htm IDEA: XBRL DOCUMENT v3.19.3

Related Party Transactions (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Related Party Transactions (Textual)

Related party payable $ 957,409 $ 279,464

X

- References
No definition available.
+ Details

Name: hybt_RelatedPartyTransactionsTextualAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount for accounts payable to related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 43 R43.htm IDEA: XBRL DOCUMENT v3.19.3

Advances from Customers (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Notes To Financial Statements Abstract

Advances from customers ^[1] $ 420,406

Total $ 420,406

[1] On October 15 2019, JSEL entered into a clinical cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

X

- References
No definition available.
+ Details

Name: hybt_NotesToFinancialStatementsAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 44 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Going Concern
9 Months Ended

Sep. 30, 2019

Going Concern [Abstract]

GOING CONCERN
NOTE 2 – GOING CONCERN

During the quarter ended September 30, 2019, the Company had been unable to generate cash flows sufficient to support its operations despite of Kangzi's business operation and had been dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $18,778,535 and working capital deficit of $686,579 as of September 30, 2019. These factors raise doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there would be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company's existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals.

X

- References
No definition available.
+ Details

Name: hybt_GoingConcernAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for going concern.
+ References
No definition available.
+ Details

Name: hybt_GoingConcernTextBlock

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Income Statement [Abstract]

Revenue, net $ 7,387 $ 57,317

Cost of Revenue 3,666 31,938

Gross Profit 3,721 25,379

Operating expenses

Selling expenses 5,992 7,377

Administrative expenses 202,505 125,957 412,207

Total operating expenses 208,497 125,957 419,584 147,797

Loss on operations (204,776) (125,957) (394,205) (147,797)

Other Income(Expenses) (370) (1,708)

Loss on operations before income taxes (205,146) (125,957) (395,913) (147,797)

Income tax expense

Net Loss (205,146) (125,957) (395,913) (147,797)

Loss attributable to noncontrolling interests (20,455) (38,697)

Net loss attributable to HYBT shareholders (184,691) (125,957) (357,216) (147,797)

Other Comprehensive Income

Foreign currency translation adjustment 12,506 15,924

Total Comprehensive Loss (172,185) (125,957) (341,292) (147,797)

Total comprehensive income attributable to noncontrolling interests (1,320) (1,546)

Total comprehensive loss attributable to HYBT shareholders $ (173,505) $ (125,957) $ (342,838) $ (147,797)

Net loss per share - basic and diluted $ (0.00) $ 0.00 $ (0.00) $ (0.00)

Weighted average shares - basic and diluted 1,019,289,346 1,032,266,000 1,660,239,731 636,661,604

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of general and administrative expense classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Expenses recognized in the period that are directly related to the selling and distribution of products or services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 46 R22.htm IDEA: XBRL DOCUMENT v3.19.3

Other Receivable (Tables)
9 Months Ended

Sep. 30, 2019

Other Receivable [Abstract]

Schedule of other receivable

As of September 30,
2019 As of December 31,
2018

Fujian Shanzhiling Biological Technology Co., Ltd. 　- 　　 21,324

Others 24,566 -

$ 24,566 $ 21,324

X

- References
No definition available.
+ Details

Name: hybt_OtherReceivableAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_ScheduleOfOtherReceivableTableTextBlock

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Advances from Customers (Tables)
9 Months Ended

Sep. 30, 2019

Advances from Customers [Abstract]

Schedule of Advances from Customers

As of
September 30,
2019 As of
December 31,
2018

Advances from customers⁽¹⁾ 420,406 -

$ 420,406 $ -



⁽¹⁾ On October 15 2019, JSEL entered into a clinical cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

X

- References
No definition available.
+ Details

Name: hybt_AdvancesfromCustomersAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes
9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

INCOME TAXES
NOTE 12 – INCOME TAXES

The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States.

Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong.

The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Other Receivable
9 Months Ended

Sep. 30, 2019

Other Receivable [Abstract]

OTHER RECEIVABLE
NOTE 4 – OTHER RECEIVABLE

Other receivable consists of the following:

As of September 30,
2019 As of December 31,
2018

Fujian Shanzhiling Biological Technology Co., Ltd. 　- 　　 21,324

Others 24,566 -

$ 24,566 $ 21,324

On October 8, 2018, the Company entered into a non-binding letter of intent with Fujian Shanzhiling Biological Technology Co., Ltd. (the "Acquirer"), a Chinese biotechnology product manufacturing corporation, whereby the Acquirer agreed to acquire 51% of the outstanding capital of the Company subject to certain adjustment provisions (the "Shanzhiling Acquisition"). As of the date of this report, the Company has terminated the agreements related to Shanzhiling Acquisition; therefore, the related balance in the amount of $24,499 has been written off during the quarter ended September 30, 2019.

X

- References
No definition available.
+ Details

Name: hybt_OtherReceivableAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_OtherReceivableDisclosureTextBlock

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Advances from Customers
9 Months Ended

Sep. 30, 2019

Advances from Customers [Abstract]

ADVANCES FROM CUSTOMERS
NOTE 8 – ADVANCES FROM CUSTOMERS



As of
September 30,
2019 As of
December 31,
2018

Advances from customers⁽¹⁾ 420,406 -

$ 420,406 $ -



⁽¹⁾ On October 15 2019, JSEL entered into a clinical cooperation agreement (the "Clinical Cooperation Agreement") with Shenzhen Saikun Biotechnology Co., Ltd. ("Saikun"). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

X

- References
No definition available.
+ Details

Name: hybt_AdvancesfromCustomersAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Advances from Customers.
+ References
No definition available.
+ Details

Name: hybt_RelatedPartyTransactionAdvancesFromCutomerssDisclosureTextBlock

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R37.htm IDEA: XBRL DOCUMENT v3.19.3

Other Receivable (Details Textual) - Fujian Shanzhiling Biological Technology Co., Ltd [Member] - USD ($)
9 Months Ended

Oct. 08, 2018

Sep. 30, 2019

Other Receivable (Textual)

Acquirer agreed to acquire outstanding capital percentage 51.00%

Acquisition related amount $ 24,499

X

- Definition
Acquirer agreed to acquire outstanding capital percentage.
+ References
No definition available.
+ Details

Name: hybt_AcquirerAgreedToAcquireOutstandingCapital

Namespace Prefix: hybt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Acquisition related amount.
+ References
No definition available.
+ Details

Name: hybt_AcquisitionRelatedAmount

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_OtherReceivableTextualAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_OwnershipAxis=hybt_FujianShanzhilingBiologicalTechnologyCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R33.htm IDEA: XBRL DOCUMENT v3.19.3

The Company and Significant Accounting Policies (Details Textual) - USD ($)
1 Months Ended

Apr. 18, 2018

Sep. 30, 2019

Sep. 01, 2019

Jan. 17, 2019

Dec. 31, 2018

The Company and Significant Accounting Policies (Textual)

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 2,000,000,000 2,000,000,000

Common stock, shares issued 1,032,466,000 1,141,472,861

Common stock, shares outstanding 1,032,466,000 1,141,472,861

operating lease right-of-use, assets $ 209,587 $ 215,298

operating lease right-of-use, lease liabilities $ 209,798 $ 215,298

Shanghai Kangzi Medical Technology Co., Ltd [Member]

The Company and Significant Accounting Policies (Textual)

Percentage of issued and outstanding shares of common stock 90.00%

JSEL [Member]

The Company and Significant Accounting Policies (Textual)

Percentage of issued and outstanding shares of common stock 60.00%

Share Purchase Agreement [Member]

The Company and Significant Accounting Policies (Textual)

Percentage of issued and outstanding shares of common stock 98.91%

Aggregate purchase price $ 335,000

Purchaser acquired shares 1,021,051,700

X

- References
No definition available.
+ Details

Name: hybt_CompanyAndSignificantAccountingPoliciesTextualAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: srt_OwnershipAxis=hybt_ShanghaiKangziMedicalTechnologyCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=hybt_JSELMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=hybt_SharePurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Advances to Suppliers
9 Months Ended

Sep. 30, 2019

Advances to Suppliers [Abstract]

ADVANCES TO SUPPLIERS
NOTE 5 – ADVANCES TO SUPPLIERS

Advances to suppliers consists of the following:

As of
September 30,
2019 As of
December 31,
2018

Prepayment for purchase of raw materials 81,431 -

$ 81,431 $ 0

X

- References
No definition available.
+ Details

Name: hybt_AdvancesToSuppliersAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_AdvancesToSuppliersTextBlock

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Accrued Expenses and Other Payables
9 Months Ended

Sep. 30, 2019

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND OTHER PAYABLES
NOTE 9 – ACCRUED EXPENSES AND OTHER PAYABLES

Accrued expenses and other payables consist of the following:

As of
September 30,
2019 As of
December 31,
2018

Accrued payroll 35,633 7,589

Other Payables 76,085 9,039

$ 111,718 $ 16,628

Accrued payroll includes all company employee payroll liabilities as of September 30, 2019, and other payables contains employee reimbursements.

Operating lease liability consist both current and noncurrent component as the following:

As of
September 30,
2019 As of
December 31,
2018

Operating lease liability - current portion (66,473 ) -

Operating lease liability (143,325 ) -

$ (209,798 ) $ -

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R19.htm IDEA: XBRL DOCUMENT v3.19.3

The Company and Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

The condensed consolidated financial statements of the Company as of and for the three and nine months ended September 30, 2019 and 2018 are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) that have been made are necessary to fairly present the financial position of the Company as of September 30, 2019, the results of its operations for the three and nine months ended September 30, 2019 and 2018, and its cash flows for the nine months ended September 30, 2019 and 2018. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The balance sheet as of December 31, 2018 has been derived from the Company's audited financial statements included in the Form 10-K for the year ended December 31, 2018.

The statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. These financial statements should be read in conjunction with the financial statements and other information included in the Company's Annual Report on Form 10-K as filed with the SEC for the fiscal year ended December 31, 2018.

As of September 30, 2019, the details of the consolidating subsidiaries are as follows:

Name of Company Place of
incorporation Attributable
equity
interest %

HP Technology Limited British Virgin Islands 100 %

Heyu Healthcare Technology Limited Hong Kong 100 %

JSEL The PRC 100 %

Kangzi The PRC 60 %

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities.

Cash Equivalents
Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company's cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation ("FDIC") insurance or any other similar insurance in the PRC, or Hong Kong.

Inventories
Inventories

Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Leases
Leases

The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements.

Operating leases are included in operating lease right-of-use ("ROU") assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.



ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.

September 1, 2019

Weighted Average Remaining Lease Term(Year) 3

Weighted Average Discount Rate 4.75 %



The approximate future minimum lease payments under operating leases as:

Operating Leases

Fiscal 2019 25,409

Fiscal 2020 77,074

Fiscal 2021 79,615

Fiscal 2022 54,206

Total Lease payments 236,304

Less Imputed interest 21,005

Present value of lease liabilities $ 215,298

Foreign Currency
Foreign Currency

For fiscal year 2019, the Company's principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company's subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders' equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. There were no gains and losses from foreign currency transactions during the quarter ended September 30, 2019 and 2018.

As of

September 30, 2019 December 31, 2018

RMB: US$ exchange rate 7.1360 6.8764

Nine months ended
September 30,

　 2019 2018

RMB: US$ exchange rate　 6.8618 6.6146

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

General and administrative costs
General and administrative costs

General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes
Income Taxes

The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain.

The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions.

The Company's policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure
Capital Structure

The Company had 2,000,000,000 shares of authorized common stock, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of September 30, 2019, and 1,141,472,861 shares issued and outstanding as of December 31, 2018.

Earnings (loss) per share
Earnings (loss) per share

Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive.

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

As of September 30, 2019 and December 31, 2018, there were no potentially dilutive shares.

For the Quarter Ended September 30,

2019 2018

Statement of Operations Summary Information:

Net loss $ (395,913 ) $ (147,797 )

Weighted-average common shares outstanding - basic and diluted 1,660,239,731 636,661,604

Net loss per share, basic and diluted $ (0.00 ) $ (0.00 )

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for leasing arrangement entered into by lessee.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980
+ Details

Name: us-gaap_LesseeLeasesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 35
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790
+ Details

Name: us-gaap_StockholdersEquityPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R36.htm IDEA: XBRL DOCUMENT v3.19.3

Other Receivable (Details) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Other receivables $ 24,566 $ 21,324

Fujian Shanzhiling Biological Technology Co., Ltd. [Member]

Other receivables 21,324

Others [Member]

Other receivables $ 24,566

X

- Definition
Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: hybt_FujianShanzhilingBiologicalAxis=hybt_FujianShanzhilingBiologicalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: hybt_FujianShanzhilingBiologicalAxis=hybt_OthersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R32.htm IDEA: XBRL DOCUMENT v3.19.3

The Company and Significant Accounting Policies (Details 4) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Statement of Operations Summary Information:

Net loss $ (184,691) $ (125,957) $ (357,216) $ (147,797)

Weighted average shares - basic and diluted 1,019,289,346 1,032,266,000 1,660,239,731 636,661,604

Net loss per share, basic and diluted $ (0.00) $ 0.00 $ (0.00) $ (0.00)

X

- References
No definition available.
+ Details

Name: hybt_CompanyAndSignificantAccountingPoliciesAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.3

Accrued Expenses and Other Payables (Details 1) - USD ($)

Sep. 30, 2019

Sep. 01, 2019

Dec. 31, 2018

Notes To Financial Statements Abstract

Operating lease liability - current portion $ 66,473

Operating lease liability 143,325

Total $ 209,798 $ 215,298

X

- References
No definition available.
+ Details

Name: hybt_NotesToFinancialStatementsAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 61 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Operating Lease Right-of-Use Asset and Liabilities (Details 2)

Sep. 30, 2019

USD ($)

Notes To Financial Statements Abstract

Fiscal 2019 $ 25,409

Fiscal 2020 77,074

Fiscal 2021 79,615

Fiscal 2022 54,206

Total Lease payments 236,304

Less Imputed interest 21,005

Present value of lease liabilities $ 215,298

X

- References
No definition available.
+ Details

Name: hybt_NotesToFinancialStatementsAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lease liabilities.
+ References
No definition available.
+ Details

Name: hybt_PresentValueOfLeaseLiabilities

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 12, 2019

Document and Entity Information [Abstract]

Entity Registrant Name Heyu Biological Technology Corp

Entity Central Index Key 0001086303

Amendment Flag false

Current Fiscal Year End Date --12-31

Document Type 10-Q

Document Period End Date Sep. 30, 2019

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2019

Entity Current Reporting Status Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Shell Company false

Entity Emerging Growth Company false

Entity Ex Transition Period false

Entity Common Stock, Shares Outstanding 1,032,466,000

Entity File Number 000-26731

Entity Interactive Data Current Yes

Entity Incorporation State Country Code NV

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_DocumentAndEntityInformationAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 64 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($)

Heyu Biological Shareholders’ Equity

Common Stock

Heyu Biological Shareholders’ Equity

Shares to be cancelled

Heyu Biological Shareholders’ Equity

Additional Paid in Capital

Heyu Biological Shareholders’ Equity

Accumulated Other Comprehensive Income

Heyu Biological Shareholders’ Equity

Accumulated Deficit

Non - controlling Interest

Total

Balance at Dec. 31, 2017 $ 150,642 $ 17,968,787 $ (18,173,542) $ (54,113)

Balance, shares at Dec. 31, 2017 150,642,240

1 for 464 reverse split $ (150,318) 150,318

1 for 464 reverse split, shares (150,317,580)

1 for 100 split $ 32,141 (32,141)

1 for 100 split, shares 32,141,340

Common stock issued April 13, 2018 $ 1,000,000 (990,000) 10,000

Common stock issued April 13, 2018, shares 1,000,000,000

Waiver of payable to ex-shareholder 52,087 52,087

Loss for the period (147,797) (147,797)

Balance at Sep. 30, 2018 $ 1,032,466 17,149,050 (18,321,339) (139,823)

Balance, shares at Sep. 30, 2018 1,032,466,000

Balance at Dec. 31, 2018 $ 1,141,473 (109,007) 17,149,050 2,567 (18,421,319) (237,236)

Balance, shares at Dec. 31, 2018 1,141,472,861

Shares cancelled March 20, 2019 $ (109,007) 109,007

Shares cancelled March 20, 2019, shares (109,006,861)

Foreign currency translation adjustment 14,378 (1,546) 12,832

Loss for the period (357,216) (38,697) (357,216)

Balance at Sep. 30, 2019 $ 1,032,466 $ 17,149,050 $ 16,945 $ (18,778,535) $ (40,243) $ (620,317)

Balance, shares at Sep. 30, 2019 1,032,466,000

X

- Definition
Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.
+ References
No definition available.
+ Details

Name: hybt_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationsAdjustmentNet

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_DebtByPriorShareholder

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
1 for 464 reverse split
+ References
No definition available.
+ Details

Name: hybt_StockIssuedDuringPeriodSharesReverseStockSplit

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
1 for 100 split
+ References
No definition available.
+ Details

Name: hybt_StockIssuedDuringPeriodSharesStockSplit

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Common stock issued shares.
+ References
No definition available.
+ Details

Name: hybt_StockIssuedDuringThePeriodSharesNewIssue

Namespace Prefix: hybt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Common stock issued.
+ References
No definition available.
+ Details

Name: hybt_StockIssuedDuringThePeriodValueNewIssue

Namespace Prefix: hybt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Reduction in the number of shares during the period as a result of a reverse stock split.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of a stock split.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockSplits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of stock bought back by the entity at the exercise price or redemption price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockRedeemedOrCalledDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 65 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Cash and Cash Equivalents
9 Months Ended

Sep. 30, 2019

Cash and Cash Equivalents [Abstract]

CASH AND CASH EQUIVALENTS
NOTE 3 – CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

As of September 30,
2019 As of December 31,
2018

Bank Deposits-China & HK 452,318 37,555

$ 452,318 $ 37,555

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Advances to Suppliers (Tables)
9 Months Ended

Sep. 30, 2019

Advances to Suppliers [Abstract]

Schedule of advances to suppliers

As of
September 30,
2019 As of
December 31,
2018

Prepayment for purchase of raw materials 81,431 -

$ 81,431 $ 0

X

- References
No definition available.
+ Details

Name: hybt_AdvancesToSuppliersAbstract

Namespace Prefix: hybt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: hybt_ScheduleOfAdvancesToSuppliersTableTextBlack

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 67 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Accrued Expenses and Other Payables (Tables)
9 Months Ended

Sep. 30, 2019

Payables and Accruals [Abstract]

Schedule of accrued expenses and other payables

As of
September 30,
2019 As of
December 31,
2018

Accrued payroll 35,633 7,589

Other Payables 76,085 9,039

$ 111,718 $ 16,628

Schedule of operating lease liability

As of
September 30,
2019 As of
December 31,
2018

Operating lease liability - current portion (66,473 ) -

Operating lease liability (143,325 ) -

$ (209,798 ) $ -

X

- References
No definition available.
+ Details

Name: hybt_ScheduleOfOperatingLeaseLiability

Namespace Prefix: hybt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

The Company and Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2019
HP Technology Limited [Member]
Name of Company	HP Technology Limited
Place of incorporation	British Virgin Islands
Attributable equity interest %	100.00%
Heyu Healthcare Technology Limited [Member]
Name of Company	Heyu Healthcare Technology Limited
Place of incorporation	Hong Kong
Attributable equity interest %	100.00%
JSEL [Member]
Name of Company	JSEL
Place of incorporation	The PRC
Attributable equity interest %	100.00%
Kangzi [Member]
Name of Company	Kangzi
Place of incorporation	The PRC
Attributable equity interest %	60.00%

Inventory (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 301,725
Finished goods	9,409
Inventory, net	$ 311,134

The Company and Significant Accounting Policies (Details 3)	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018
US$ exchange rate			6.6146
RMB [Member]
US$ exchange rate	7.1360	6.8764
US$ exchange rate	6.8618

Related Party Transactions (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Related Party Transactions (Textual)
Related party payable	$ 957,409	$ 279,464

Other Receivable (Details Textual) - Fujian Shanzhiling Biological Technology Co., Ltd [Member] - USD ($)		9 Months Ended
	Oct. 08, 2018	Sep. 30, 2019
Other Receivable (Textual)
Acquirer agreed to acquire outstanding capital percentage	51.00%
Acquisition related amount		$ 24,499

Other Receivable (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Other receivables	$ 24,566	$ 21,324
Fujian Shanzhiling Biological Technology Co., Ltd. [Member]
Other receivables		21,324
Others [Member]
Other receivables	$ 24,566

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 12, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	Heyu Biological Technology Corp
Entity Central Index Key	0001086303
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		1,032,466,000
Entity File Number	000-26731
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV

Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($)	Heyu Biological Shareholders’ Equity Common Stock	Heyu Biological Shareholders’ Equity Shares to be cancelled	Heyu Biological Shareholders’ Equity Additional Paid in Capital	Heyu Biological Shareholders’ Equity Accumulated Other Comprehensive Income	Heyu Biological Shareholders’ Equity Accumulated Deficit	Non - controlling Interest	Total
Balance at Dec. 31, 2017	$ 150,642		$ 17,968,787		$ (18,173,542)		$ (54,113)
Balance, shares at Dec. 31, 2017	150,642,240
1 for 464 reverse split	$ (150,318)		150,318
1 for 464 reverse split, shares	(150,317,580)
1 for 100 split	$ 32,141		(32,141)
1 for 100 split, shares	32,141,340
Common stock issued April 13, 2018	$ 1,000,000		(990,000)				10,000
Common stock issued April 13, 2018, shares	1,000,000,000
Waiver of payable to ex-shareholder			52,087				52,087
Loss for the period					(147,797)		(147,797)
Balance at Sep. 30, 2018	$ 1,032,466		17,149,050		(18,321,339)		(139,823)
Balance, shares at Sep. 30, 2018	1,032,466,000
Balance at Dec. 31, 2018	$ 1,141,473	(109,007)	17,149,050	2,567	(18,421,319)		(237,236)
Balance, shares at Dec. 31, 2018	1,141,472,861
Shares cancelled March 20, 2019	$ (109,007)	109,007
Shares cancelled March 20, 2019, shares	(109,006,861)
Foreign currency translation adjustment				14,378		(1,546)	12,832
Loss for the period					(357,216)	(38,697)	(357,216)
Balance at Sep. 30, 2019	$ 1,032,466		$ 17,149,050	$ 16,945	$ (18,778,535)	$ (40,243)	$ (620,317)
Balance, shares at Sep. 30, 2019	1,032,466,000